10 franchise brands scored by real SBA loan performance data.
Showing 1-10 of 10 franchises in Pharmacies and Drug Stores
The American healthcare system leaves millions of patients underserved by the impersonal, transaction-oriented model of corporate chain pharmacies. Long wait times, pharmacists too overwhelmed to counsel patients, language barriers, and one-size-fits-all service models create a real vacuum in community health delivery — particularly for elderly patients, non-English speakers, and those managing complex chronic conditions. 986 Pharmacy was built to fill exactly that gap. Founded in 2014 under the parent company 986 Degrees Corporation, the brand was co-founded by Dr. Ken Thai, Vijay Amarshi, Dr. Henry Chang, and Sally Chan, Esq. — a team comprising three pharmacists, a lawyer, and a creative professional who collectively brought clinical depth, legal rigor, and operational creativity to the independent pharmacy model. The first physical location opened in 2015 in La Verne, California, and the brand has since expanded to include seven franchised retail locations across Southern California, four specialty pharmacies operating across California, Nevada, and Texas, and an infusion pharmacy launched in Anaheim, California, in 2017. With 8 total units currently operating, 7 of which are franchised and the remaining company-owned units at zero, 986 Pharmacy is a lean but purposefully structured franchise system. The brand's fourth specialty pharmacy opened in Pasadena, California, in 2020, and its most recent expansion into Koreatown was completed in May 2023. For franchise investors evaluating the 986 Pharmacy franchise opportunity, this analysis is produced independently by PeerSense and is not sponsored, approved, or reviewed by 986 Degrees Corporation. The pharmacy services industry in North America represents a total addressable market that commanded a 53.2% global revenue share in 2024, and within that landscape, the 986 Pharmacy franchise occupies a differentiated, community-focused niche that is structurally positioned to benefit from the secular shift away from chain pharmacy consolidation. The pharmacy industry is one of the most durable and macro-supported categories in franchise investment, driven by demographic inevitabilities and chronic disease prevalence that are immune to recessionary cycles. The global pharmacy market was estimated at USD 1.35 trillion in 2024 and is projected to reach USD 2.06 trillion by 2030, representing a compound annual growth rate of 7.3% between 2025 and 2030. Longer-range projections are even more aggressive: the global pharmacy market is estimated at USD 2,337.97 billion in 2025, with forecasts projecting growth to USD 4,569.34 billion by 2034 at a CAGR of 7.81%. The retail pharmacy segment specifically was worth approximately USD 689 billion globally in 2023 and is projected to reach USD 1,693 billion by 2032, growing at a CAGR of roughly 10.5% between 2024 and 2032. In the United States alone, prescription drug sales through retail pharmacies exceeded 364 billion USD in 2022, and the country accounted for over 40% of the global retail pharmacy market that same year. The secular tailwinds driving this growth are well-documented: an aging population with escalating medication needs, rising prevalence of chronic diseases, expanded Medicare and Medicaid coverage, and growing demand for specialty and compounding medications. The prescription segment dominated the global pharmacy market with a revenue share of 81.3% in 2024, reinforcing the centrality of Rx volume as a value driver in any pharmacy franchise investment. Independent pharmacies are projected to hold the largest distribution channel market share in retail pharmacy over the forecast period, creating an opening for branded independent models like the 986 Pharmacy franchise to capture outsized portions of this secular growth. The competitive environment, while dominated at the brand-recognition level by large institutions, is structurally fragmented at the community service layer — precisely the layer where 986 Pharmacy competes with personalized clinical care, multilingual staffing, and same-day delivery infrastructure. The 986 Pharmacy franchise investment requires a total capital commitment ranging from $150,000 on the low end to $895,000 on the high end, reflecting the significant variability between a conversion of an existing pharmacy operation and a full ground-up buildout with specialty or infusion capabilities. Cross-referencing this against other published data points, one source cited a total investment range of $279,700 to $671,000, while another noted down payments for E2 visa-eligible investments starting at $100,000, confirming the franchise's accessibility to a range of investor profiles including international investors pursuing U.S. residency through the E2 visa program. The upfront franchise fee has been cited across various sources between $50,000 and $75,000, placing it in the mid-tier range for healthcare-adjacent franchise systems where fees frequently exceed $100,000 for medically complex service models. In the broader franchising industry, royalty rates typically range from 4% to 8% of gross sales, and advertising fund contributions generally fall between 1% and 3% of sales, providing a structural benchmark for modeling total ongoing fee obligations for the 986 Pharmacy franchise investment. The parent company, 986 Degrees Corporation, has a documented banking relationship with East West Bank dating to approximately 2012, with CEO Dr. Ken Thai citing SBA loan support as a key enabler of the company's early-stage growth — a relationship that may signal favorable SBA lending history for prospective franchisees seeking debt financing for their 986 Pharmacy franchise cost. The franchise system is currently not registered in states that require franchise registration, meaning prospective investors located in non-registration states should engage directly with 986 Degrees Corporation to confirm current registration status before advancing to due diligence. For investors comparing 986 Pharmacy franchise cost against category peers, the investment range is consistent with independent pharmacy conversions and below the threshold of many healthcare franchise systems that require significant clinical buildout and equipment procurement. The 986 Pharmacy operating model is built around a high-touch, clinically enriched service delivery framework that demands an engaged, community-oriented franchisee rather than an absentee investor. Daily operations span retail prescription dispensing, specialty medication management, compounding services, infusion therapy, immunization programs, and medication therapy management — a breadth of clinical services that differentiates 986 Pharmacy locations from transactional chain competitors. The franchise's target service territory is defined as a 15-mile radius from the pharmacy location, with a strategic emphasis on elderly patients who generate disproportionately high prescription volume due to age-related chronic disease burden. Staffing is multilingual by design: 986 Pharmacy locations operate with team members fluent in English, Spanish, Mandarin, Cantonese, Korean, Vietnamese, Armenian, Farsi, and Russian, enabling the franchise to penetrate diverse urban and suburban community markets that are systematically underserved by monolingual chain pharmacies. The brand's operational philosophy extends to logistics: free daily local medication delivery is offered six days per week, and the brand has described its two-hour doorstep delivery capability as competitive with on-demand e-commerce fulfillment. Pharmacist training emphasizes patient-level personalization, with staff trained to recognize customers by face and name and to recall individual medication histories — a clinical customer experience standard that is difficult for high-volume chain competitors to replicate at scale. A documented case study involving Dr. Lilia Xu, Vice President of Business Development at 986 Degrees Corporation and owner-operator of 11 stores within the 986 Pharmacy Group network, demonstrated that the franchise system supports multi-unit operators with operational tools including Cardinal Health Reconciliation Plus powered by EnlivenHealth, which reduced accounts receivable reconciliation from an unmanageable manual burden to 1-2 hours per month across all 11 stores and achieved zero outstanding claims over 60 days — a meaningful operational benchmark for investors modeling cash flow management in a multi-unit 986 Pharmacy franchise portfolio. Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for the 986 Pharmacy franchise, meaning prospective franchisees cannot rely on a franchisor-provided revenue benchmark when modeling unit-level economics. This is a material consideration in any due diligence process, and investors should request current FDD documents directly from 986 Degrees Corporation and consult with an independent franchise attorney before signing. While FDDs from 2017, 2018, 2019, and 2020 have been referenced as available through third-party FDD aggregators, the content of those documents' Item 19 sections has not been independently verified as containing specific gross revenue or net profit disclosures. In the absence of disclosed financial performance data, investors can contextualize unit-level revenue potential using industry benchmarks: the U.S. retail pharmacy market generated prescription drug sales exceeding 364 billion USD in 2022, and independent pharmacies serving Medicare and Medicaid populations — which 986 Pharmacy explicitly targets — benefit from recurring, insurance-reimbursed prescription volume with predictable refill cycles. Specialty pharmacy is a particularly high-value revenue segment; the specialty drug market is growing at rates meaningfully above the broader Rx market due to the increasing pipeline of biologic and oncology therapies requiring specialized dispensing and patient management. The franchise system reported 15 stores in operation as of January 2019, creating 203 jobs and serving over 50,000 patients — metrics that imply an average of roughly 3,333 patients per location at that point in the network's development, a patient census consistent with independently operating community pharmacies in suburban Southern California markets. Investors should also engage directly with existing 986 Pharmacy franchisees, including multi-unit operators within Dr. Lilia Xu's 11-store network, to solicit unfiltered perspectives on revenue trajectory, payer dynamics, and operating cost structures before committing capital to a 986 Pharmacy franchise investment. The 986 Pharmacy franchise has demonstrated a consistent and accelerating growth trajectory since the first location opened in La Verne, California, in 2015. The franchise model itself was formalized in 2019 as part of a long-term strategic positioning to enable independent ownership within a branded, system-supported structure — a decision that aligned with the broader national trend toward independent pharmacy consolidation under franchise umbrellas. By January 2019, the network had already scaled to 15 stores, generating 203 jobs and serving over 50,000 patients, before the current FDD-reported unit count of 8 reflects what appears to be a subsequent restructuring or recalibration of the network footprint. The brand's multi-state presence — operating in California, Nevada, and Texas — demonstrates geographic diversification beyond its Southern California origin market. The leadership team provides a meaningful competitive moat: CEO Dr. Ken Thai holds a Doctoral degree from USC School of Pharmacy, has over 20 years of pharmacy experience, served as immediate-Past President of the California Pharmacists Association, and currently serves as an Adjunct Assistant Professor of Pharmacy Practice at both USC School of Pharmacy and Western University of Health Sciences, where he teaches entrepreneurship. Co-founder Dr. Henry Chang also holds a USC School of Pharmacy doctorate with over 20 years of independent and long-term care pharmacy ownership experience. Co-founder Sally Chan, Esq. serves as Vice President of Compliance and brings specialized expertise in business, real estate, and employment litigation through her firm West Themis Law, founded in 2008 and currently operating with her as managing partner. Co-founder Vijay Amarshi contributes digital marketing infrastructure through his prior founding of PCYNE, a digital marketing company, providing the franchise system with a growth-oriented digital acquisition capability. The franchise's expansion into Koreatown in May 2023 signals continued appetite for urban densification in multilingual Southern California markets where the brand's linguistic and clinical service model delivers a structural competitive advantage. The ideal 986 Pharmacy franchisee is a healthcare-oriented entrepreneur or licensed pharmacist seeking to build an owner-operated or lightly managed community pharmacy business within a branded support infrastructure. While pharmacist licensure is not explicitly stated as a requirement, the clinical complexity of compounding, infusion, and specialty medication services within the 986 Pharmacy operating model strongly favors candidates with pharmacy or healthcare management backgrounds who can credibly oversee clinical operations and maintain regulatory compliance. The franchise system has demonstrated openness to multi-unit development, as evidenced by Dr. Lilia Xu's management of 11 stores across multiple states within the 986 Pharmacy Group network, suggesting that high-performing franchisees can scale significantly within the system. Geographic focus remains concentrated in California, Nevada, and Texas, with California — and particularly Southern California's diverse urban and suburban corridor — representing the brand's deepest market penetration and most developed operational infrastructure. The 15-mile territory radius creates meaningful local market exclusivity for franchisees willing to invest in community relationship building, particularly with assisted living facilities, boarding care homes, and 340B clinics, all of which represent recurring institutional revenue streams. Prospective franchisees interested in the E2 visa investment pathway should note that the franchise has been cited as eligible for E2 investment with entry points beginning at $100,000 in down payment, creating a relevant entry pathway for internationally based investors. The franchise's staff development culture — where employees have historically progressed into management roles and partnership opportunities — suggests a growth-oriented internal talent pipeline that benefits franchisees in competitive labor markets for pharmacy professionals. For investors conducting serious due diligence on the 986 Pharmacy franchise opportunity, the investment thesis rests on several converging factors: a massive and accelerating global pharmacy market projected to exceed USD 2.06 trillion by 2030 at a 7.3% CAGR, a differentiated community-pharmacy model with multilingual clinical staffing and specialty service capabilities, a leadership team with over 40 combined years of pharmacy ownership and operational experience, and an initial investment range of $150,000 to $895,000 that is accessible relative to many healthcare franchise categories. The FPI Score of 46, rated Fair by the independent PeerSense scoring methodology, reflects the early-stage franchise system characteristics — limited disclosed unit count, absence of Item 19 financial performance data, and constrained geographic registration — that warrant heightened due diligence rather than automatic disqualification. The pharmacy sector's structural immunity to e-commerce disruption at the clinical services layer, combined with 986 Pharmacy's specialty and infusion capabilities that chain competitors cannot replicate at community scale, creates a defensible long-term positioning thesis. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark the 986 Pharmacy franchise investment against competing pharmacy and healthcare franchise opportunities across cost, support quality, and growth trajectory dimensions. Explore the complete 986 Pharmacy franchise profile on PeerSense to access the full suite of independent franchise intelligence data and make your investment decision with the most comprehensive, unbiased analysis available anywhere on the internet.
The modern consumer navigates an increasingly intricate healthcare landscape, often feeling like a mere transaction within vast, impersonal systems, particularly concerning their fundamental pharmaceutical needs. This challenge is magnified by the widespread consolidation of pharmacy chains and the dwindling presence of truly independent, community-focused drug stores, leaving many individuals yearning for accessible, trusted, and personalized healthcare solutions within their immediate neighborhoods. This growing gap creates a profound problem: how can individuals access high-quality, personalized pharmacy care while maintaining a sense of community connection and trust in an era of corporate giants? Good Neighbor Pharmacy emerges as a direct and potent solution to this pervasive consumer need, positioning itself as the indispensable guide for both patients seeking tailored care and independent pharmacists striving to retain their local identity and entrepreneurial spirit. While specific founding dates for Good Neighbor Pharmacy are not available, its inherent operational philosophy clearly stems from a deep-rooted commitment to empowering the independent pharmacy model, likely evolving in direct response to the escalating demand for community-centric healthcare solutions that prioritize personalized patient relationships over sheer volume. The brand's strategic operational hub is located in BEVERLY HILLS, CA, from which it supports its expansive network. Good Neighbor Pharmacy currently operates at a significant scale, comprising 16 total units, every single one of which is a franchised location. This 100% franchised model underscores a deliberate strategy focused on licensee empowerment and a pure-play franchise approach, rather than relying on company-owned outlets. Good Neighbor Pharmacy distinctively positions itself as the unwavering champion of the independent pharmacist, furnishing them with the essential tools, comprehensive resources, and a recognized branding framework necessary to not only compete effectively but to thrive against the formidable scale of larger corporate chains, all while meticulously preserving their invaluable local identity and the hallmark of personalized patient service. This specific niche is not merely a preference but a critical, underserved segment within the broader U.S. pharmacy market. The total addressable market (TAM) for the U.S. retail pharmacy sector, which encompasses the critical functions of prescription fulfillment, the sale of over-the-counter medications, and a growing array of ancillary health services, represents a colossal economic segment, with current estimates placing its annual value well in excess of $450 billion. Projections indicate a robust trajectory for continued expansion, with the market expected to approach or even exceed $600 billion by the mid-2020s. This substantial growth is primarily propelled by an aging demographic, the increasing prevalence of chronic diseases across the population, and a steady rise in overall prescription volumes. Good Neighbor Pharmacy operates squarely within this expansive, essential, and continuously growing healthcare sector, offering a vital service to communities nationwide. The U.S. pharmacy market, a critical component of the national healthcare infrastructure, is currently valued at over $450 billion and is projected to exhibit a robust compound annual growth rate (CAGR) of 4-6% over the next five years. This sustained expansion is underpinned by significant demographic shifts and prevailing healthcare trends. A primary driver is the aging population, with individuals aged 65 and older constituting an increasingly larger demographic segment. This demographic shift directly translates into higher prescription volumes and an elevated demand for specialized chronic disease management services, creating a foundational tailwind for the entire industry. Key consumer trends are also significantly shaping demand within the pharmacy sector. Modern consumers are increasingly prioritizing convenience, seeking highly personalized care experiences, and desiring integrated health services that extend well beyond the simple act of prescription pickup. There is a discernible and growing preference for local establishments that cultivate a strong sense of community and trust, offering a stark contrast to the often impersonal and transactional experiences associated with large corporate pharmacy chains. Furthermore, the demand for easily accessible health screenings, a wider range of immunizations, and comprehensive medication therapy management (MTM) within a familiar and trusted community setting is demonstrably on the rise, reflecting a shift in consumer expectations towards more holistic pharmaceutical care. Several powerful secular tailwinds are also propelling the industry forward. The ongoing paradigm shift towards value-based care models, the gradual but significant expansion of the pharmacist's scope of practice, and the increasing reliance on pharmacies as crucial front-line healthcare access points – particularly in geographically underserved areas – represent substantial drivers of growth. The pervasive digital transformation occurring across the broader healthcare landscape, including the accelerated adoption of telehealth services and sophisticated online prescription management platforms, also presents myriad opportunities for innovative, integrated operating models within the pharmacy sector. This convergence of factors makes the industry exceptionally attractive for franchise investment. The inherently essential nature of pharmacy services provides a strong degree of recession-resilience, offering stability even during economic downturns. The consistently high demand for healthcare services, coupled with the compelling opportunity to cultivate a community-centric business model that generates reliable recurring revenue streams from prescription refills and fosters deeply loyal customer bases, positions the pharmacy sector as a highly appealing franchise opportunity. Moreover, the existing robust regulatory framework and established operational infrastructure provide a stable and predictable operating environment for new entrants. The competitive dynamics within this market are characterized by significant fragmentation, with large national chains, numerous regional players, and thousands of independent pharmacies all actively vying for market share. Good Neighbor Pharmacy’s distinctive model strategically focuses on empowering the independent segment to not only survive but to thrive within this intensely competitive landscape, effectively leveraging hyper-local relationships and highly personalized service as critical differentiators against the sheer scale and brand recognition of larger corporate competitors. For prospective investors considering a Good Neighbor Pharmacy franchise, a thorough understanding of the financial commitment is paramount. While the specific franchise fee for a Good Neighbor Pharmacy franchise is not publicly available, it is instructive to consider typical franchise fees within the broader retail and healthcare sectors. These initial fees commonly range from $30,000 to $60,000, representing the upfront cost for accessing the franchisor's established brand systems, comprehensive training protocols, and proprietary operational blueprints. This initial outlay is a standard and expected component of nearly all franchise agreements, serving to compensate the franchisor for the valuable intellectual property and foundational support provided at the outset of the partnership. The total initial investment required to establish a Good Neighbor Pharmacy franchise spans a significant and broad range, from a minimum of $655,000 at the lower end to an extensive $4.18 million at the higher end. This substantial variance in investment is a clear indicator of the diverse operational formats, market conditions, and strategic choices that a pharmacy owner might encounter. Numerous factors contribute to this wide range, including the physical size and strategic location of the facility, whether the project involves a completely new build-out or the acquisition and integration of an existing pharmacy business, the initial inventory requirements for both prescription and over-the-counter products, the sophistication of the technology infrastructure, and the essential initial working capital needed to sustain operations through the crucial ramp-up phase. For instance, the establishment of a full-service pharmacy in a high-traffic urban center, demanding extensive custom build-out, advanced equipment, and a comprehensive, diverse inventory, would naturally gravitate towards the higher end of this investment spectrum. Conversely, a smaller, more specialized community pharmacy in a less competitive market, potentially leveraging an existing structure and requiring fewer modifications, might comfortably fall within the lower range of the investment. While specific liquid capital and net worth requirements for a Good Neighbor Pharmacy franchise are not available, it is a well-established practice for franchise investments of this magnitude, potentially reaching up to $4.18 million, to necessitate substantial liquid assets. Typically, franchisors require liquid capital equivalent to 20-30% of the total investment, along with a net worth requirement that can be two to three times the total investment. These rigorous financial benchmarks are absolutely crucial for ensuring a franchisee possesses the necessary capacity to adequately fund the initial setup, manage unforeseen operational expenses, and maintain robust operational stability, particularly given the inventory-heavy nature and regulatory complexities inherent in the pharmacy business. Similarly, the specific royalty and advertising fees for a Good Neighbor Pharmacy franchise are not available. However, within the broader franchise ecosystem, ongoing royalty fees typically range from 4% to 8% of gross revenues, providing franchisees with continuous access to brand updates, evolving operational support, and system-wide enhancements. Advertising fees, if applicable, usually fall between 1% and 3% of gross revenues, contributing to the system-wide marketing and brand promotion efforts that benefit all franchisees. These recurring fees are fundamental to the franchisor's ability to continually invest in the brand's growth, innovation, and the sustained support of its franchisees. The total cost of ownership for a Good Neighbor Pharmacy franchise extends well beyond the initial investment and any potential ongoing fees. It comprehensively encompasses critical elements such as real estate costs (whether through lease or outright purchase), continuous inventory replenishment, payroll for licensed pharmacists and support staff, comprehensive insurance coverage, all necessary regulatory compliance expenses, and ongoing technology upgrades to remain competitive. Given that the average annual revenue for a well-managed independent pharmacy can range from $2.5 million to $4 million, diligent and strategic management of all these operating costs is paramount to achieving consistent profitability and realizing a strong return on the significant initial investment. The FPI Score of 59 (Moderate) assigned to Good Neighbor Pharmacy suggests a balanced risk-reward profile, indicating that while the financial commitment is substantial, the established support system, brand recognition, and inherent market demand for pharmacy services collectively mitigate some of the intrinsic operational risks. The daily operations of a Good Neighbor Pharmacy franchise are typically multifaceted, revolving primarily around the core functions of prescription dispensing, comprehensive medication therapy management, personalized patient counseling, and the strategic sale of over-the-counter (OTC) medications and various health-related products. Routine daily activities encompass precise inventory management, efficient processing of complex insurance claims, proactive engagement with prescribing physicians and other healthcare providers, and the delivery of consistently personalized customer service. A fundamental emphasis is placed on cultivating strong, enduring patient relationships and establishing the pharmacy as an indispensable, trusted healthcare resource within its local community. This patient-centric approach distinguishes the Good Neighbor Pharmacy model. Operating a pharmacy of this scale generally necessitates a dedicated and skilled team, typically comprising licensed pharmacists, certified pharmacy technicians, and administrative or retail support staff. A representative independent pharmacy might employ 2-4 licensed pharmacists, 3-6 pharmacy technicians, and 1-2 front-end staff members, with specific numbers contingent upon the average daily prescription volume, the breadth of service offerings, and the operational hours. The precise staffing model is critical for maintaining strict regulatory compliance, effectively managing workload fluctuations, and ensuring the consistent delivery of high-quality patient care. While specific format options for a Good Neighbor Pharmacy franchise are not explicitly detailed, the expansive initial investment range, spanning from $655,000 to $4.18 million, strongly suggests a significant degree of operational flexibility. This adaptability could manifest in various formats, potentially including traditional standalone community pharmacies, pharmacies strategically integrated within larger medical clinics or healthcare centers, or even smaller, more specialized units designed to focus on particular patient populations or niche health services. The operational model likely emphasizes the ability to adapt to diverse local market needs and leverage available real estate opportunities efficiently. Although specific details regarding the training program for a Good Neighbor Pharmacy franchise are not available, a robust and comprehensive program within the highly regulated pharmacy sector would typically encompass extensive instruction on operational procedures, proficiency in pharmacy management software, advanced inventory control techniques, adherence to all pertinent regulatory compliance (including HIPAA regulations and state boards of pharmacy mandates), best practices in customer service, and effective local marketing strategies. Initial training would most likely involve a combination of structured classroom instruction and practical, hands-on experience, often spanning several intensive weeks, thereby thoroughly preparing franchisees for all critical facets of pharmacy ownership and day-to-day management. Good Neighbor Pharmacy, as a franchisor, would be expected to provide continuous and multifaceted support to its 16 franchised units. This ongoing support would typically include regular operational guidance, privileged access to preferred vendor networks for pharmaceuticals and essential supplies (potentially leading to significant cost savings and optimized inventory management), comprehensive marketing assistance, timely technology updates, and continuous educational opportunities for both franchisees and their staff. This robust support system is absolutely critical for independent pharmacies to remain competitive, compliant, and relevant in the rapidly evolving and complex healthcare landscape. While specific territory structures are not available, franchise models commonly offer exclusive territories, meticulously defined by geographical boundaries or population density. This structure ensures that franchisees have a protected area in which to develop and grow their business without direct competition from other brand units, a design intended to maximize local market penetration and enhance franchisee success. Given that all 16 existing Good Neighbor Pharmacy units are franchised, the model inherently supports single-unit ownership. However, for an experienced operator who consistently demonstrates strong performance, robust financial capacity, and a proven track record, the potential for multi-unit development could certainly exist, allowing them to expand their footprint across multiple communities. Prospective investors considering a Good Neighbor Pharmacy franchise must be aware that Item 19 financial performance data is NOT disclosed in the current Franchise Disclosure Document (FDD). This means that specific figures regarding revenue, gross profit, net profit, or detailed expense breakdowns for existing Good Neighbor Pharmacy franchise locations are not provided directly by the franchisor. While this absence necessitates a different analytical approach, it is important to note that non-disclosure of Item 19 data is not uncommon within the broader franchise industry, particularly for brands that may prioritize other forms of franchisee support or are still in the process of establishing consistent financial reporting standards across a network that may encompass diverse operational models. In the absence of specific Good Neighbor Pharmacy financial data, investors must prudently rely on broader industry benchmarks for independent pharmacies to formulate their financial projections. The average annual revenue for a well-managed independent retail pharmacy in the United States typically ranges from $2.5 million to $4 million, with high-volume, strategically located operations occasionally exceeding $5 million annually. Gross profit margins for prescription drug sales, which constitute the core of most pharmacy businesses, generally range from 20% to 28%. Front-end sales, encompassing over-the-counter medications, health and beauty products, and general merchandise, often yield higher gross margins, sometimes upwards of 35-45%, contributing significantly to overall profitability. After accounting for all operating expenses, net profit margins for independent pharmacies typically fall between 2% and 4%, though exceptionally efficient operations in favorable market conditions can achieve net margins of 5-7%. The overall pharmacy market is experiencing robust growth, as previously discussed, with prescription drug spending projected to increase by 4-6% annually. This sustained and predictable demand provides a strong foundational layer for pharmacy profitability. The evolving role of pharmacies as primary care access points, increasingly offering services such as immunizations, diagnostic screenings, and chronic disease management programs, further enhances revenue potential beyond traditional prescription dispensing. Several key factors critically influence the financial performance of an independent Good Neighbor Pharmacy franchise. These include the average daily prescription volume, the payer mix (which refers to the blend of insurance plans accepted and their respective reimbursement rates), the efficiency and sophistication of inventory management systems, the effectiveness of local marketing and community engagement initiatives, and the diligent ability to control operating costs such as payroll, rent, and utilities. The strategic implementation of enhanced patient services, such as medication synchronization programs, adherence packaging, and comprehensive health screenings, can also significantly boost revenue per patient and improve overall operational profitability. The FPI Score of 59 (Moderate) for Good Neighbor Pharmacy, while not directly tied to specific financial disclosures, suggests that the brand offers a viable franchise opportunity that warrants careful consideration. This moderate score indicates a balanced profile, implying that while the potential for success is present, it inherently requires a well-executed business plan, strong operational management by the franchisee, and a thorough understanding of local market dynamics to maximize financial outcomes. The absence of Item 19 data means that the FPI Score calculation would likely rely more heavily on other qualitative and quantitative factors such as overall brand strength, the comprehensiveness of operational support provided, and the general viability of the market segment, rather than direct, reported financial performance metrics. Prospective Good Neighbor Pharmacy franchisees should therefore prioritize developing detailed pro forma financial statements based on conservative industry averages, rigorous local market research, and realistic operational assumptions. This comprehensive financial modeling should include projecting diverse revenue streams from both prescription and front-end sales, meticulously estimating direct costs (e.g., cost of goods sold for pharmaceuticals), and forecasting all operating expenses. A robust and well-articulated financial model will be absolutely essential for critically assessing the viability of the investment, securing necessary financing, and navigating the operational landscape, particularly in the absence of franchisor-provided financial performance representations. Good Neighbor Pharmacy currently operates with a stable network of 16 total units, all of which are exclusively franchised. This 100% franchised model, with zero company-owned units, distinctly signifies a dedicated, franchise-centric growth strategy. While specific historical data on year-over-year unit growth trends for Good Neighbor Pharmacy are not explicitly available, the consistent existence of 16 active locations within the PeerSense database clearly indicates a foundational network that has been successfully established, maintained, and supported over time. Without specific historical data, the precise rate of net new unit additions for Good Neighbor Pharmacy cannot be definitively determined. However, in a highly competitive market where independent pharmacies frequently face intense pressure from larger corporate chains, maintaining a consistent and stable network of 16 franchised units is itself a testament to resilience and a focused strategy aimed at effectively supporting existing operators. Future growth for Good Neighbor Pharmacy will likely stem from strategic expansion into identified underserved communities or geographic areas where the demand for accessible, personalized pharmacy services is demonstrably high and growing. While specific recent developments for Good Neighbor Pharmacy are not explicitly available, the broader independent pharmacy sector has undergone significant advancements in technology adoption. These include the widespread implementation of enhanced pharmacy management systems, seamless telehealth integration, sophisticated automated dispensing solutions, and advanced patient engagement platforms. To remain acutely competitive and to provide robust support to its franchisees, Good Neighbor Pharmacy would logically be investing in or providing its network with access to such cutting-edge innovations, thereby ensuring that its affiliated pharmacies remain at the forefront of modern pharmaceutical care delivery. The continuous emphasis on proactive community engagement and the optimization of patient outcomes remains a perpetual area of development and strategic focus for all independent pharmacies seeking long-term viability. The primary competitive moat for a Good Neighbor Pharmacy franchise is deeply embedded in its unwavering commitment to the independent pharmacy model. This model effectively empowers local pharmacists by providing them with a recognized brand identity and a comprehensive support structure, all while allowing them to meticulously retain their entrepreneurial spirit and invaluable community ties. This approach stands in stark contrast to the often impersonal and standardized operational methodologies of large corporate chains. The "Good Neighbor" brand itself intrinsically evokes powerful sentiments of trust, familiarity, and personalized care, which are immeasurably valuable differentiators within the sensitive healthcare sector. Furthermore, franchisees benefit significantly from access to preferred vendor relationships, the sharing of best practices across the network, and collective marketing resources through the overarching franchise system. These advantages provide a significant competitive edge that individual, standalone independent pharmacies often struggle to secure on their own. The unique ability to leverage a collective brand identity and shared resources while meticulously preserving local autonomy and personalized service creates a powerfully synergistic blend of scale and individualized care. In an increasingly digital world, a successful and forward-thinking pharmacy network must proactively embrace technological advancements. While specific digital initiatives for Good Neighbor Pharmacy are not detailed, a robust franchise system in this category would typically offer comprehensive support for online prescription refills, secure patient communication portals, intuitive mobile applications for medication reminders, and sophisticated data analytics tools designed to optimize operational efficiencies and enhance patient care. Such advanced digital capabilities significantly enhance patient convenience, improve medication adherence rates, and streamline internal workflow, all contributing substantially to a Good Neighbor Pharmacy’s operational efficiency and its competitive edge in the market. These technological tools are absolutely crucial for meeting the evolving expectations of the modern consumer and for strategically expanding the pharmacy’s patient reach. The ideal Good Neighbor Pharmacy franchisee is most typically a licensed pharmacist or a highly experienced healthcare professional who possesses a strong entrepreneurial drive and an unwavering commitment to community health and wellness. Such an individual brings not only the critical clinical expertise required to competently operate a pharmacy but also robust business acumen, encompassing essential skills in financial management, effective staff leadership, and the cultivation of strong customer relationships. A genuine passion for delivering personalized patient care, a nuanced understanding of local market dynamics, and a proactive willingness to actively engage with and serve the community are absolutely paramount for success. Given the substantial initial investment range, from $655,000 to $4.18 million, prospective candidates must also demonstrate significant financial capacity, stability, and access to the necessary capital. The FPI Score of 59 (Moderate) suggests that while the brand offers a supportive framework, a proactive, highly capable, and experienced franchisee is essential for navigating the inherent complexities of the pharmacy business and achieving sustained long-term success. With all 16 current units being franchised, the Good Neighbor Pharmacy model is primarily structured to support individual owner-operators. However, for an exceptional franchisee who consistently demonstrates exemplary operational performance, robust financial health, and a proven ability to effectively manage multiple locations, the opportunity for multi-unit development could potentially be explored. This would likely involve a strategic, in-depth discussion with the franchisor, focusing on factors such as market saturation, the franchisee's operational readiness, and their long-term vision for expansion. While specific available territories for a Good Neighbor Pharmacy franchise are not detailed, the brand's pure-play franchise model and moderate FPI Score suggest that strategic expansion is likely a key focus. Opportunities would typically be identified in markets that are currently underserved by independent pharmacies or in areas experiencing population growth and an increasing demand for accessible, personalized healthcare services. Prospective franchisees should engage directly with the Good Neighbor Pharmacy development team to discuss specific market availability and to review demographic analyses that support new unit placement. The timeline for opening a Good Neighbor Pharmacy franchise can vary significantly, heavily influenced by factors such as real estate acquisition, specific build-out requirements, the intricate process of obtaining necessary licensing, and securing all regulatory approvals. Typically, for a pharmacy operation, this comprehensive process can range from 9 to 18 months, especially if a new facility needs to be constructed or extensively renovated. Acquiring an existing pharmacy might potentially shorten this timeframe, but it still necessitates thorough due diligence, the legal transfer of licenses, and the seamless integration into the Good Neighbor Pharmacy system. While the specific term length for a Good Neighbor Pharmacy franchise agreement is not available, standard franchise agreements within the healthcare sector typically range from 10 to 20 years, often with options for renewal. These extended terms provide a sufficiently long window for franchisees to realize a substantial return on their significant initial investment and to build considerable equity in their business, while also enabling the franchisor to maintain brand consistency and execute long-term strategic planning effectively. The Good Neighbor Pharmacy franchise presents a compelling investment opportunity for experienced healthcare professionals and astute entrepreneurs who are strategically seeking to capitalize on the resilient and consistently growing U.S. pharmacy market. With an initial investment range spanning from $655,000 to $4.18 million, this pure-play franchise model, currently comprising 16 active units, is meticulously designed to empower independent pharmacists to thrive by leveraging a recognized brand identity and a robust, comprehensive support system. While specific Item 19 financial disclosures are not available in the current FDD, the industry's consistent growth trajectory, which is powerfully driven by an aging population and an increasing demand for personalized patient care, provides a strong and stable foundation for potential profitability, with average independent pharmacy revenues often exceeding $2.5 million annually. The FPI Score of 59 (Moderate) assigned to Good Neighbor Pharmacy further underscores a balanced risk-reward profile, emphasizing the critical importance of a strong, capable operator in a sector fundamentally defined by essential services and deep community trust. Good Neighbor Pharmacy offers a unique and viable path to ownership within a critical healthcare segment, adeptly combining the intrinsic benefits of local entrepreneurship with the strategic advantages of a supportive network, thereby positioning franchisees to effectively meet the evolving and diverse needs of their communities. For investors seeking to navigate the intricacies of this significant franchise opportunity and gain deeper, independent insights into its substantial potential, comprehensive, unbiased analysis is absolutely indispensable. Explore the complete Good Neighbor Pharmacy franchise profile on PeerSense to access the full suite of independent franchise intelligence data, competitive benchmarks, and strategic insights essential for making an informed investment decision in this vital sector.
Deciding whether to invest in a restaurant franchise is one of the most consequential financial decisions a person can make, and the stakes are never higher than when the brand in question sits outside the conventional franchise infrastructure most investors rely on for due diligence. Johnny Tamale Cantina Licens represents precisely that kind of opportunity — a locally rooted, authentically positioned Tex-Mex concept with deep community ties and a documented operating history that stretches back to 1998, when the Pasadena, Texas location first opened its doors. The brand's origin story is grounded in family: Troy, the younger brother of the founder of Gringo's Mexican Kitchen, built the Johnny Tamales concept around humble beginnings, authentic Tex-Mex cuisine served from day one, and the kind of generational loyalty that corporate chains spend hundreds of millions of dollars trying to manufacture. The Missouri City, Texas location — a newly constructed 9,500 square foot restaurant — is currently positioned for sale as a going-concern business opportunity, and its co-location adjacent to a 10,500 square foot pickleball facility scheduled to open in late 2026 creates a forward-looking foot traffic thesis that distinguishes it from static legacy restaurant assets. The Johnny Tamale Cantina Licens franchise opportunity currently registers a single operating unit, reflecting its status as a locally managed, independently structured concept rather than a national franchise system with hundreds of development commitments. The total addressable market for Tex-Mex and broader Mexican-American restaurant cuisine in the United States exceeds $50 billion annually, with the casual dining and fast-casual segments capturing the largest share of consumer spending in this category. For investors who understand the difference between a proven independent brand with genuine community equity and a commoditized franchise system, the Johnny Tamale Cantina Licens franchise opportunity demands serious, eyes-open analysis — and that is exactly what this profile delivers. The restaurant franchise industry operates within one of the most resilient and consistently growing segments of the American consumer economy. The broader U.S. restaurant industry generates over $1 trillion in annual sales, and the Tex-Mex and Mexican food segment accounts for one of the most visited cuisine categories in the country, driven by demographic tailwinds including the growing Hispanic-American population, which now exceeds 62 million people and represents the fastest-growing consumer demographic in the United States. The fast-casual Mexican food segment alone has grown at rates that consistently outpace full-service dining, with consumer preference data showing that authenticity, value, and speed of service rank as the top three purchase drivers in this category. The secular tailwind here is not subtle: American consumers are eating Mexican-inspired food more frequently than any cuisine outside of burgers and pizza, and independent concepts with authentic positioning — as opposed to chain brands perceived as manufactured and uniform — are capturing an outsized share of repeat visits. The restaurant franchise sector broadly attracts significant investment capital precisely because of its combination of tangible asset value, established operating systems, and brand-driven consumer demand; according to industry data, the restaurant sector represents the single largest category of franchise investment in the United States, comprising roughly 30% of all franchise units in operation. For an investor evaluating the Johnny Tamale Cantina Licens franchise opportunity, the macro environment is unambiguously favorable for well-positioned Tex-Mex concepts with authentic brand heritage and community-embedded operating histories. The Missouri City, Texas market itself is a high-growth suburban corridor within the Houston metropolitan statistical area — the fourth-largest city in the United States by population — providing a demand environment that supports long-term restaurant revenue growth as the suburban population continues to expand. Evaluating the Johnny Tamale Cantina Licens franchise cost requires an honest acknowledgment of what is known and what must be benchmarked against industry standards, because the brand does not currently operate within a formalized franchise disclosure framework that generates publicly filed FDD data. No specific franchise fee has been filed or disclosed for Johnny Tamale Cantina Licens. For context on what this category of opportunity typically requires, general restaurant franchise industry benchmarks are instructive: initial franchise fees across the restaurant sector range from $10,000 on the low end for brands like Domino's to $90,000 for established QSR concepts like Dunkin', with the typical mid-market restaurant franchise fee falling between $30,000 and $50,000. Total investment ranges for restaurant franchises span from approximately $200,000 on the lean end for conversion or non-traditional formats to well over $2.5 million for full ground-up builds in premium markets; a January 2024 industry benchmark cited a representative total investment range of $1.5 million to $2.5 million inclusive of a $45,000 franchise fee for a mid-scale restaurant concept. The Missouri City Johnny Tamales location is a newly constructed 9,500 square foot facility, which suggests a build-out investment consistent with ground-up restaurant construction in the Houston suburban market — a cost environment where restaurant construction per square foot ranges from $200 to $400 depending on finish level, implying a facility investment alone in the range of $1.9 million to $3.8 million before equipment, FF&E, and working capital. Ongoing royalty rates for restaurant franchises typically fall between 4% and 8% of gross sales, with marketing fund contributions generally running an additional 1% to 5% of gross sales. The Johnny Tamale Cantina Licens franchise investment profile, while not formally disclosed through a standard FDD, fits within the broader mid-to-premium investment range for full-service casual dining concepts in high-growth Texas suburban markets. The daily operating model for Johnny Tamale Cantina Licens reflects the demands and rhythms of a full-service casual dining restaurant concept rather than a quick-service or fast-casual format. The 9,500 square foot Missouri City facility is purpose-built for full-service dining, implying a front-of-house staffing model that typically requires 15 to 30 employees depending on shift structure, service volume, and the degree to which the owner-operator is personally present in daily operations. The Pasadena, Texas location has operated continuously since 1998, providing over 26 years of operational institutional knowledge that represents a meaningful intangible asset for any incoming operator or license holder evaluating the Johnny Tamale Cantina Licens franchise opportunity. The Missouri City location's positioning adjacent to the incoming 10,500 square foot pickleball facility — anticipated to open in late 2026 — creates a cross-marketing and foot traffic dynamic that operators of complementary food and entertainment businesses have exploited successfully across markets nationwide, with entertainment-adjacent restaurant concepts consistently outperforming isolated locations by 15% to 30% in revenue-per-seat metrics according to hospitality industry research. Full-service Tex-Mex concepts of this format typically require owner-operators who are hands-on in management, particularly in the first two to three years of operation, with the labor intensity of the model generally requiring the franchisee or license holder to be actively engaged in hiring, training, food quality management, and community marketing. The brand's documented legacy across Texas communities — described explicitly as "a beloved local brand that has served the community for decades" — provides incoming operators with an existing customer base and brand recognition that materially reduces the new-customer acquisition burden that typically plagues cold-start restaurant openings in new markets. Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for Johnny Tamale Cantina Licens, which means prospective investors cannot access verified average unit volume, median revenue, or top-quartile earnings benchmarks through the standard FDD review process. This is a meaningful due diligence consideration, and investors should approach it the same way a disciplined analyst would approach any investment without a public income statement: by constructing a revenue estimate from operational parameters and industry benchmarks. A 9,500 square foot full-service Tex-Mex restaurant in a high-growth Houston suburban corridor, operating with full lunch and dinner service, can reasonably be benchmarked against industry data showing that full-service casual dining restaurants in the United States generate average annual revenues of $1.0 million to $2.5 million depending on location quality, seating capacity, and brand strength. The Missouri City location is specifically described as "primed for long-term growth and profitability" based on its strategic positioning, newly constructed facility, and the incoming pickleball facility adjacency expected to drive sustained incremental traffic beginning in late 2026. Restaurant profit margins in the casual dining segment typically range from 3% to 9% at the net income level, with top-performing operators in high-traffic suburban markets achieving EBITDA margins of 12% to 18% before occupancy costs. The Pasadena location's 26-year operating history since 1998 provides a rare longitudinal data point suggesting that the underlying business model is economically durable across multiple economic cycles, including the 2008 financial crisis, the 2020 pandemic-driven restaurant industry contraction — which eliminated approximately 110,000 restaurant locations nationally — and the inflationary environment of 2021 through 2023 that compressed margins across the restaurant sector. Prospective investors should request historical financial statements, tax returns, and point-of-sale revenue records directly from the seller or licensor as part of a comprehensive due diligence process for the Johnny Tamale Cantina Licens franchise investment. The growth trajectory of Johnny Tamale Cantina Licens reflects the realities of an independently operated, community-anchored brand rather than a venture-backed franchise system pursuing aggressive unit expansion. The two confirmed locations — Pasadena, Texas, operating since 1998, and Missouri City, Texas, a newly constructed 9,500 square foot facility — represent the current physical footprint of the Johnny Tamales concept within the Houston metropolitan area. The Missouri City location's new construction signals a deliberate investment in brand expansion, with the 9,500 square foot facility representing a significantly scaled-up format compared to the average new restaurant construction in the QSR and fast-casual segment, where non-traditional formats average 1,500 to 3,000 square feet. The brand's competitive moat is built on authentic Tex-Mex cuisine, multi-decade community relationships, and the kind of locally embedded customer loyalty that translates into sustained repeat visit frequency — the single most important driver of restaurant unit economics in any market. The Missouri City location's proximity to the incoming pickleball facility creates a forward-looking growth catalyst that is particularly timely: pickleball is the fastest-growing sport in the United States, with over 36 million players reported in 2023, and food and beverage operators adjacent to pickleball facilities have documented revenue uplifts driven by pre- and post-play dining occasions. For investors evaluating the Johnny Tamale Cantina Licens franchise opportunity within the context of a longer-term development strategy, the Houston metropolitan area's population — currently approximately 7.3 million and projected to reach 9 million by 2040 — provides a structurally expanding demand base that supports incremental location development across the region's rapidly growing suburban corridors. The ideal candidate for the Johnny Tamale Cantina Licens franchise opportunity is an experienced restaurant operator or entrepreneurially minded investor with a genuine affinity for Tex-Mex cuisine and an understanding of community-driven hospitality businesses. Given the full-service format of the 9,500 square foot Missouri City facility, candidates with prior experience managing front-of-house operations, food service labor scheduling, and local marketing programs will have a structural advantage over investors with purely financial backgrounds and no operational restaurant experience. The Houston metropolitan area's demographic composition — with one of the largest and most food-culturally engaged Hispanic-American communities in the United States — creates a customer base that rewards authentic positioning and penalizes inauthenticity, meaning that operators who genuinely understand the cuisine and the culture will outperform those who treat it as a commodity. The Missouri City location's current availability as a going-concern sale inclusive of the business and real estate represents a relatively rare structure in restaurant franchise transactions, as most franchise acquisitions involve a separation between real estate ownership and business operations; combined real estate and business acquisitions eliminate ongoing lease risk, provide asset-backed collateral value, and create optionality for future refinancing or asset monetization. The franchise agreement term structure for this concept has not been publicly disclosed, which is a standard characteristic of independently managed restaurant licensing arrangements rather than formal franchise systems with FTC-mandated FDD disclosures. Prospective buyers and license holders should conduct a thorough legal review of any licensing, operating, or purchase agreement before committing capital, engaging qualified franchise counsel with Texas food service transaction experience. For investors conducting serious due diligence on restaurant franchise opportunities in the Houston metropolitan market, Johnny Tamale Cantina Licens presents a genuinely distinctive case study: a brand with 26 years of proven operating history since 1998, a newly constructed 9,500 square foot flagship facility positioned adjacent to a major incoming entertainment amenity, a deeply loyal community customer base in one of the fastest-growing metropolitan markets in the United States, and a Tex-Mex cuisine category that benefits from powerful demographic and consumer preference tailwinds. The current FPI Score of 38, rated Fair, reflects the early-stage or limited-disclosure nature of the franchise structure rather than a fundamental flaw in the underlying business, and investors should interpret this score as a signal to conduct deeper independent due diligence rather than a disqualifying indicator. The broader restaurant franchise sector in the United States generates over $350 billion in annual system-wide sales across more than 400,000 franchise units, and Tex-Mex concepts with authentic brand positioning have consistently demonstrated above-average customer retention metrics compared to generic fast-food categories. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark the Johnny Tamale Cantina Licens franchise opportunity against competing restaurant concepts across every relevant investment metric — from total investment range and royalty structure to unit count growth trajectories and territory availability. The combination of a proven brand, a strategically located newly constructed facility, a high-growth suburban Texas market, and the forward-looking pickleball facility adjacency catalyst creates an investment thesis that rewards thorough due diligence and penalizes superficial analysis. Explore the complete Johnny Tamale Cantina Licens franchise profile on PeerSense to access the full suite of independent franchise intelligence data and make your investment decision with the analytical rigor this opportunity deserves.
Franchise investors often grapple with the inherent complexities of selecting a robust business model within highly regulated and competitive sectors, a challenge compounded by the significant capital commitment required and the fear of misjudging market viability. Medicap Pharmacy emerges as a structured pathway into the essential healthcare services industry, offering a proven operational framework designed to mitigate these investment risks. Founded in 1971 in Des Moines, Iowa, though one source also indicates a founding year of 1972, the brand originated as "Medicine Chest," an innovative retail prototype aimed at synergizing patient care, convenience, and cost savings in pharmaceutical services. The company began franchising in 1973, with another source stating 1974, quickly establishing a network that would expand significantly over the decades. Medicap Pharmacy operates under Medicine Shoppe International (MSI), which is a part of Cardinal Health, a major player in the healthcare sector, providing substantial corporate backing and resources. Medicap Pharmacies Inc. was acquired by Medicine Shoppe International, Inc. in December 2003, at which point it was a franchisor of 181 community pharmacies spread across 34 states. While the main office for Medicap Pharmacy remains in West Des Moines, Iowa, it also benefits from corporate facilities in Dublin, Ohio. The Medicap Pharmacy franchise model currently consists of 56 total units, with 96 franchised units and 0 company-owned units, demonstrating a pure franchise operational strategy. The total addressable market for this category is immense, with the global pharmacy market valued at USD 2.4 trillion in 2024 and projected to reach USD 4.1 trillion by 2035, underscoring the significant and enduring demand for pharmaceutical services. This comprehensive Medicap Pharmacy franchise analysis by PeerSense provides the critical, independent intelligence essential for informed investment decisions in this vital and expanding sector. The pharmacy market represents a substantial and dynamically growing industry, presenting a compelling landscape for a Medicap Pharmacy franchise investment. The global pharmacy market size was estimated at USD 1.35 trillion in 2024 and is anticipated to reach USD 2.06 trillion by 2030, or alternatively, estimated at USD 1.49 trillion in 2025 and expected to reach USD 1.96 trillion by 2030. Another estimate places the global pharmacy market at USD 1,315.2 billion in 2023, predicted to reach USD 1,914.6 billion by 2032, further reinforced by a valuation of USD 2.4 trillion in 2024, expected to grow to USD 2.5 trillion in 2025 and USD 4.1 trillion by 2035. This robust expansion is supported by impressive compound annual growth rates (CAGR) ranging from 4.3% (2023-2032) to 7.3% (2025-2030), with a 5% CAGR projected for the 2024-2035 period. Key consumer trends driving this sustained demand include stable healthcare needs and an aging demographic, which directly contribute to increasing prescription volumes. A significant secular tailwind benefiting the Medicap Pharmacy franchise is the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions, which affect approximately 133 million Americans, leading to a surge in healthcare spending and an escalating demand for prescription medications. This industry category attracts franchise investment due to its essential nature and recession-resistant characteristics. Competitive dynamics are evolving, with a notable shift towards customer-centric business models, prompting pharmacies to invest in advanced analytics and personalization technologies to enhance the customer experience. Macro forces creating significant opportunity include the projected rapid growth of the Over-the-Counter (OTC) products segment at an impressive CAGR of 7-8% from 2025 to 2030, and the e-pharmacy segment, which is anticipated to expand at a CAGR of 12-13% during the same period, driven by high internet usage and patients' desire to reduce healthcare costs. Furthermore, the industry is witnessing increased integration of digital prescription management systems and the emergence of value-based care models, enhancing distribution efficiency and offering new avenues for a Medicap Pharmacy franchise to thrive. The financial commitment required for a Medicap Pharmacy franchise investment varies significantly, reflecting different business models and market conditions. The franchise fee for a Medicap Pharmacy franchise is stated as $50,000 in the provided database, which stands in contrast to web research findings that indicate a range of $3,000 to $15,000, with other sources suggesting "up to -", "$0 - $0", or even a figure as high as $193,940, highlighting the importance of consulting the most recent Franchise Disclosure Document. The total initial investment for a Medicap Pharmacy franchise, according to the database, ranges from $50,000 to $408,680. Web research provides a broader average initial investment range of $130,000 to $961,000 for a Medicap Pharmacy franchised center. Specifically, opening a new Medicap Pharmacy business is estimated to cost between $478,050 and $961,440, while converting an existing pharmacy into a Medicap Pharmacy franchise requires an investment ranging from $130,000 to $582,440. Other sources present additional overall investment ranges, including $22,100 to $447,000, $330,050 to $699,414, $330,050 to $690,039, and $130,000 to $894,876. These investment ranges significantly exceed sub-sector averages of $294,531 - $623,123, reflecting the specialized nature of pharmaceutical operations, stringent regulatory requirements, and the necessity for specific inventory and equipment. Ongoing fees for a Medicap Pharmacy franchise include a royalty fee of 3% of gross sales and a marketing and advertising fee of 1% of gross sales, which contribute to brand development and operational support. Prospective applicants are typically expected to have a minimum liquid capital of about $55,000 to cover startup obligations and initial cash flow needs, with another source suggesting a minimum cash required ranging from $65,000 to a higher-end figure, and working capital listed as $50,000 to $70,000. Medicap Pharmacy operates under Medicine Shoppe International (MSI), which is a part of Cardinal Health, a major healthcare company, providing significant corporate backing and potential access to financing considerations. Given the investment ranges and specialized nature, a Medicap Pharmacy franchise represents a mid-to-premium tier franchise investment, requiring substantial capital due to its specialized nature and the essential services it provides. The operating model for a Medicap Pharmacy franchise is designed to integrate patient care with efficient pharmaceutical services, supported by a comprehensive corporate infrastructure. Daily operations for a franchisee typically involve managing prescription fulfillment, providing a range of expanded health services, and fostering strong community relationships. While specific staffing requirements are not explicitly detailed, the operational scope, which includes immunizations, point-of-care testing, one-on-one consultations, medication packaging, medication synchronization, diabetes care supplies, medical equipment, glucose testing, and cholesterol screening, necessitates a team of qualified pharmacists and support staff to ensure high-quality patient care and efficient service delivery. Medicap Pharmacy provides comprehensive initial training for new franchisees, although one source states an initial training program of 0 hours, which could imply a focus on experienced pharmacists or specific pre-qualification requirements. Item 11 of the Franchise Disclosure Document would contain detailed information on the length and specific content of the training program. The ongoing corporate support for a Medicap Pharmacy franchise is robust, featuring a dedicated Franchise Business Consultant (FBC) who serves as a crucial sounding board for strategic business growth and operational refinement. Franchisees also benefit from a broader corporate team that assists with complex compliance requirements and targeted marketing initiatives. This support system includes expert consultants specializing in marketing, managed care, operations, and finance, providing a well-rounded suite of resources. Medicap Pharmacy offers a turnkey approach to help franchisees launch and operate their businesses efficiently, providing core services that meet the unique needs of independent pharmacy owners, including vital assistance with choosing an optimal location and managing complex reimbursement processes. Furthermore, franchisees gain access to a valuable network of pharmacists, fostering collaboration for sharing best practices and enabling performance benchmarking against similar stores, which enhances operational excellence. Territory structure is strategically defined, with ideal locations for new Medicap Pharmacy franchises typically found in communities with aging demographics, limited existing pharmacy competition, strong healthcare infrastructure, and stable economic indicators. Prospective franchisees are encouraged to focus on communities with populations between 10,000 and 50,000, particularly in areas with limited access to personalized pharmacy services, indicating a strategic focus on underserved markets. Regarding financial performance, the current Franchise Disclosure Document for Medicap Pharmacy does not disclose Item 19 financial performance data. This means specific average revenue, median revenue, or profit margins are not publicly provided by the franchisor, making a direct unit-level financial performance assessment challenging for prospective investors. Web research findings corroborate this, explicitly stating "N/A Average Gross Revenue" from multiple sources, indicating a consistent absence of this detailed financial information. While direct revenue figures for a Medicap Pharmacy franchise are undisclosed, the broader industry context provides a valuable framework for evaluating potential. The global pharmacy market, a substantial and growing sector, was estimated at USD 1.35 trillion in 2024 and is projected to reach USD 2.06 trillion by 2030, with other estimates placing it at USD 2.4 trillion in 2024 and expected to reach USD 4.1 trillion by 2035, demonstrating a robust and expanding market environment. This market growth, driven by a CAGR ranging from 4.3% to 7.3% over various forecast periods, suggests a strong underlying demand that can support a Medicap Pharmacy franchise. Medicap Pharmacy's historical growth trajectory, from 28 pharmacies in Iowa by 1981 to reaching its 100th location in 1993, and its current network of 96 franchised units (56 total units), signifies a resilient operational model that has successfully sustained expansion over several decades. As of 2020 FDD data, Medicap Pharmacy had franchise locations in 24 states, with the Midwest region having a substantial presence of 41 locations, indicating a proven operational model in specific geographic markets. Operating under Medicine Shoppe International, which is part of Cardinal Health, provides a Medicap Pharmacy franchise with significant corporate backing and access to extensive industry resources, which can indirectly support unit-level performance and competitive positioning. The industry trend of pharmacies expanding services beyond traditional prescription filling to include immunizations, point-of-care testing, and specialized consultations, creates multiple potential revenue streams that a Medicap Pharmacy franchise can leverage to enhance its financial viability within a competitive market. Although direct financial performance data is not available, the Medicap Pharmacy franchise investment, ranging from $50,000 to $408,680 (from franchise data) or $130,000 to $961,000 (from web research), must be assessed against the backdrop of high, consistent demand in an essential services sector, fueled by the increasing prevalence of chronic diseases affecting 133 million Americans and an aging demographic. Medicap Pharmacy has demonstrated a consistent growth trajectory since its inception, marking significant milestones throughout its history. By 1981, the network had expanded to 28 pharmacies within Iowa, showcasing early regional success. The brand’s expansion beyond Iowa began in 1984 with the opening of a Medicap Pharmacy in Minnesota, signaling a broader strategic vision. A significant milestone was reached in 1993 when the 100th Medicap Pharmacy opened for business, underscoring its established presence. Current unit counts present some variability across sources, with 56 total units and 96 franchised units reported in the franchise database. Web research indicates approximately 54 locations, 67 US Franchises, and 77 franchised Medicap Pharmacy locations in the USA as per the 2020 Franchise Disclosure Document, while one source even indicates 237 units in operation. Together, Medicine Shoppe International (MSI) and Medicap Pharmacy stores form a combined network of more than 800 locations in the United States and over 400 in five other countries, illustrating the substantial overall footprint and scale achieved under the parent company. A pivotal corporate development was the acquisition of Medicap Pharmacies Incorporated by Medicine Shoppe International, Inc. in December 2003, at which time Medicap had 181 community pharmacies across 34 states. This acquisition integrated the Medicap Pharmacy franchise into a larger, more resourced corporate structure under Cardinal Health, providing a significant competitive advantage. The brand's competitive moat is created by its established recognition, its operational integration into the Cardinal Health ecosystem, which provides supply chain scale and technological resources, and its foundational commitment to personalized patient care and convenience. The Medicap Pharmacy franchise is actively adapting to current market conditions by expanding its service offerings beyond traditional prescription filling to include immunizations, point-of-care testing, and one-on-one consultations, thereby becoming "one-stop-shops" and capitalizing on evolving healthcare needs. The industry’s digital transformation, including the rapid growth of the e-pharmacy segment at a CAGR of 12-13% from 2025 to 2030, is an area where the backing of Cardinal Health likely provides significant resources for digital integration and competitive positioning. The proven operational model in the Midwest, with 41 locations across 24 states as of 2020 FDD data, provides a clear blueprint for replication and continued growth in similar underserved markets. The ideal Medicap Pharmacy franchise candidate is typically an individual with a strong professional background in pharmacy or a related healthcare field, possessing the requisite licenses and a deep understanding of pharmaceutical operations and patient care. While specific experience requirements are not explicitly detailed, the specialized nature and regulatory environment of a pharmacy business suggest that candidates with prior management experience, particularly within a healthcare setting, would be well-suited to navigate daily operations and lead a team. A commitment to community health and patient-centric service is paramount for success within the Medicap Pharmacy franchise model. Prospective franchisees should strategically focus on communities with populations between 10,000 and 50,000, particularly those exhibiting aging demographics, limited existing pharmacy competition, robust local healthcare infrastructure, and stable economic indicators, as these markets offer optimal conditions for a new Medicap Pharmacy franchise. Significant expansion opportunities for a Medicap Pharmacy franchise are identified in underserved markets across the Northeast and Southeast regions, building upon the brand’s established operational model and success in the Midwest. While the specific timeline from signing a franchise agreement to opening a Medicap Pharmacy is not provided, the comprehensive support system and turnkey approach offered by the franchisor, including assistance with location selection and reimbursement management, are designed to streamline the launch process. The franchise agreement term length is also not specified, a crucial detail for long-term planning that prospective investors would clarify during the due diligence process. Investing in a Medicap Pharmacy franchise offers a compelling opportunity to enter the resilient and expanding pharmaceutical market, which is projected to reach USD 4.1 trillion by 2035, driven by stable healthcare demand, aging demographics, and the increasing prevalence of chronic diseases affecting approximately 133 million Americans. Despite variations in reported unit counts, such as 56 total units, 96 franchised units, or 77 franchised units in the 2020 FDD, the brand's long history dating back to 1971 and its strategic integration into the Cardinal Health ecosystem provide a stable foundation and access to significant industry resources. The Medicap Pharmacy franchise model’s strategic focus on underserved markets and communities with populations between 10,000 and 50,000, coupled with the expansion of services beyond traditional prescriptions, positions it to capitalize on evolving consumer needs and comprehensive healthcare trends. While Item 19 financial performance data is not disclosed, a thorough due diligence process, informed by robust industry benchmarks and the brand's extensive operational support, is essential for evaluating the potential return on a Medicap Pharmacy franchise investment, which ranges from $50,000 to $408,680. PeerSense provides exclusive due diligence data including SBA lending history, an FPI score of 54 (Moderate), location maps with Google ratings, FDD financial data, and side-by-side comparison tools, offering unparalleled independent franchise intelligence. Explore the complete Medicap Pharmacy franchise profile on PeerSense to access the full suite of independent franchise intelligence data.
For franchise investors navigating the complex and critical healthcare sector, the fundamental question often revolves around identifying opportunities that combine an essential service with a proven, patient-centric model. Medicine Shoppe International franchise presents itself as a compelling option within the pharmacies and drug stores category, offering pharmacists and independent investors a pathway into community-focused pharmaceutical care. The brand's deep roots trace back to 1968 when St. Louis pharmacist Michael Busch first established The Medicine Shoppe pharmacy, driven by a mission to deliver personalized service and pharmacist-managed care directly to his community. Recognizing the scalable potential of this patient-first philosophy, Busch founded Medicine Shoppe International, Inc. (MSI) in 1970, also based in St. Louis, Missouri, specifically to extend franchise-ownership opportunities, leading to the opening of the first franchised Medicine Shoppe pharmacy in 1971. Today, the PeerSense database indicates 94 total units, all of which are franchised, reflecting a pure-play franchise model. However, broader industry reports from 2025/2026 suggest a more expansive presence, with nearly 500 locations operating across the United States, including 297 owned by franchisees, while a February 2026 report specifies approximately 365 stores across 43 U.S. states complemented by over 120 international locations. Historically, the brand has demonstrated significant scale, with over 600 locations nationwide reported as early as 1973 and 595 total stores in 2013. Medicine Shoppe International’s global footprint extends beyond the United States to include Canada, China, India, Indonesia, and Japan, further solidified by an expansion into the Middle East in 2007 with five Medicine Shoppe pharmacies in Dubai, United Arab Emirates, through a master franchise agreement with the Al Zahrawi Group, marking its seventh country of operation. This extensive and evolving operational history, coupled with its acquisition by Cardinal Health in 1995 and subsequent expansion through the acquisition of Medicap Pharmacies Inc. in 2003, positions Medicine Shoppe International as a historically significant and strategically backed entity within the pharmaceutical services market. The brand’s enduring focus on patient-centered community pharmacies, providing a critical local healthcare resource, makes it a pertinent consideration for investors seeking a stable, impactful role in the healthcare delivery ecosystem, distinguishing it from more transactional retail pharmacy models. The industry landscape for pharmacies and drug stores, the core category for Medicine Shoppe International franchise, is characterized by its essential nature and sustained demand, underpinned by several robust secular tailwinds. While specific total addressable market size and growth rate figures for this exact category are not provided in the research, the healthcare sector as a whole represents a multi-trillion-dollar economy in the U.S., with pharmaceutical services forming a foundational component. Key consumer trends are unequivocally driving demand for community pharmacies: an aging global population necessitates increased medication management and chronic disease care, fostering a greater reliance on accessible local pharmacists. Furthermore, a growing health consciousness among consumers, coupled with a preference for personalized service over impersonal large-chain interactions, directly aligns with Medicine Shoppe International’s founding mission of pharmacist-managed, patient-centered care. The increasing complexity of prescription medications and the ongoing shift towards preventative health and wellness further amplify the role of community pharmacists as trusted healthcare advisors. These macro forces create a resilient environment for franchise investment in this industry, as pharmacy services are largely recession-resistant and benefit from recurring customer needs. The competitive dynamics within the pharmacy sector are a blend of highly consolidated large national chains and a fragmented network of independent and franchised community pharmacies. Medicine Shoppe International, with its focus on a premium franchise opportunity within the Alternative Care sub-sector, carves out a distinct niche by emphasizing high-touch patient relationships and a pharmacist-driven model, differentiating itself from the volume-driven strategies of larger competitors. The ongoing demand for localized healthcare access, particularly in underserved regions, coupled with the trust inherent in a long-standing community pharmacy brand, generates significant opportunity for the Medicine Shoppe International franchise network to expand its footprint and deepen its market penetration. The continuous evolution of healthcare policies, often favoring community-based care and preventative services, also provides a supportive regulatory environment for this type of franchise model. For prospective investors considering a Medicine Shoppe International franchise investment, understanding the financial architecture is paramount, positioning it as a substantial and premium opportunity within the Alternative Care sub-sector. The initial franchise fee structure exhibits some nuance across recent Franchise Disclosure Documents (FDDs). While the 2025 and 2026 FDD data predominantly lists the initial franchise fee as $0, reflecting a potentially attractive entry point for some programs, one specific 2026 document also noted a $10,000 fee for new franchisees, suggesting variations based on specific programs or agreements. This fee structure is noteworthy, especially when compared to the broader franchise market, where initial fees can often range from $25,000 to $50,000 or more. The total investment required to open a Medicine Shoppe International franchise is substantial, ranging from $478,000 to $961,000, according to the 2025/2026 FDD data. This range exceeds the sub-sector averages of $294,531 to $623,123, firmly establishing Medicine Shoppe International as a premium investment. Other FDD data points reinforce this, with a 2024 FDD indicating a range of $513,050 to $894,876, and a 2026 FDD stating $513,050 to $895,653. The spread in investment is primarily driven by factors such as the scale of leasehold improvements, which can range from $55,000 to $175,000, and the opening inventory requirements, set between $95,000 and $170,000. A detailed breakdown of initial expenditures from the 2025 FDD further clarifies the capital deployment: Furniture, Fixtures & Equipment at $42,000 – $95,000; Pre-Opening Costs from $3,000 – $10,000; Signs & Installation at $15,000 – $35,000; Grand Opening and Marketing from $4,000 – $34,000; Accounts Receivable Financing at $60,000 – $100,000; Computer and Pharmacy Equipment at $26,000 – $40,000; Retail Solutions from $0 – $14,075; Telepharmacy from $0 – $35,865; and Accreditation Costs from $3,050 – $7,500. Additionally, franchisees must allocate $175,000 – $245,000 for Additional Funds to cover the first three months of operation. Beyond the initial investment, Medicine Shoppe International franchisees are subject to ongoing fees: a royalty rate of 5% of gross sales as per 2025 data, though other 2026 data indicates a 3.00% royalty fee. For licensing a co-branded or full-branded store, a flat monthly fee of $599 is mentioned for a five-year term in 2026 data. Franchisees also contribute to an advertising fund, typically 1% of gross sales, supporting collective marketing efforts. The substantial total investment and ongoing fee structure underscore the commitment required for this franchise opportunity, reflecting the comprehensive nature of establishing and operating a patient-centered community pharmacy backed by a global healthcare services and products company like Cardinal Health, Inc., which acquired MSI in 1995. Cardinal Health, Inc. is headquartered in Dublin, Ohio, and as of April 2023, Brad Cochran serves as the Executive Vice President of retail distribution at Cardinal Health and President of Medicine Shoppe International Inc. (MSI), providing strong corporate leadership. The operating model for a Medicine Shoppe International franchise is intrinsically linked to its founding mission of delivering personalized service and pharmacist-managed care, making the franchisee's role highly engaged and community-focused. Daily operations for a franchisee revolve around direct patient interaction, prescription fulfillment, medication therapy management, and offering a range of health and wellness services tailored to the local community's needs. The emphasis on "pharmacist-managed care" strongly implies an owner-operator model, where the franchisee, ideally a pharmacist or a hands-on investor, is deeply involved in the day-to-day clinical and business aspects of the pharmacy. While specific staffing requirements are not detailed, a typical community pharmacy necessitates a team including pharmacists, pharmacy technicians, and administrative support staff to ensure efficient and compliant operations. The format options, though not explicitly delineated as drive-thru or kiosk, are inherently designed for a community retail presence, evidenced by the significant investment allocated to Leasehold Improvements, ranging from $55,000 to $175,000, and Signs & Installation, between $15,000 and $35,000, suggesting a dedicated physical storefront. Medicine Shoppe International, backed by Cardinal Health, provides a robust framework of ongoing corporate support designed to empower its franchisees. This support extends beyond initial setup to include strategic guidance from field consultants, access to technology platforms essential for modern pharmacy operations, and comprehensive marketing programs funded by the 1% advertising fee on gross sales. The supply chain leverage provided by Cardinal Health, a global healthcare services and products company, is a critical advantage, ensuring access to a wide array of pharmaceutical products and efficient distribution channels. While specific details on the initial training program's duration or location are not available, the complexity of operating a pharmacy franchise implies comprehensive instruction covering operational procedures, patient care protocols, and business management. The brand's territory strategy demonstrates a concentrated presence in the Northeast and Midwest of the U.S., with particular strength in Pennsylvania and New York, complemented by solid secondary markets in Missouri, Indiana, and New Jersey. Medicine Shoppe International currently operates in 36 states plus Washington D.C., with the largest regional concentration of 98 franchise locations situated in the South, according to 2024 FDD data. This strategic geographical focus indicates established brand recognition and market penetration in these areas, while also highlighting opportunities for expansion in lighter-covered Southeast and Western regions. The franchise agreement term length is noted as a five-year term for licensing a co-branded or full-branded store, providing a clear operational horizon for franchisees. For potential investors in a Medicine Shoppe International franchise, the absence of Item 19 financial performance data in the current Franchise Disclosure Document necessitates a nuanced approach to assessing unit-level economics. While specific average revenue, median revenue, or profit margins are not disclosed directly by the franchisor, a comprehensive understanding can be constructed through industry benchmarks, the brand's market positioning, and its historical growth trajectory. The substantial total investment range of $478,000 to $961,000, positioned as a "premium franchise opportunity" exceeding the Alternative Care sub-sector averages, implies an expectation of significant revenue generation and robust unit-level profitability to justify such a capital outlay. The ongoing royalty rates, specified as 5% of gross sales (2025 data) or 3.00% (other 2026 data), along with a 1% advertising fund contribution, are structured to support both franchisor services and a healthy franchisee return, suggesting a business model designed for strong performance. The long history of Medicine Shoppe International, having evolved significantly since its founding in 1968 and its acquisition by Cardinal Health in 1995, indicates a sustainable business model that has adapted through various economic cycles. The strategic expansion, including the acquisition of Medicap Pharmacies Inc. in 2003 and global ventures into countries like Canada, China, India, Indonesia, Japan, and the UAE, where it established five pharmacies in Dubai in 2007, further attests to the perceived value and operational viability of the brand. Unit count trends, while showing some fluctuations over decades, provide a historical context for the brand's scale. An older report from 1973 mentioned over 600 locations nationwide, peaking at 595 total stores in 2013. Data from 2010 showed 473 franchised locations, which subsequently decreased to 292 by 2024. However, more recent reports from 2025/2026 indicate nearly 500 locations across the United States, with 297 owned by franchisees, and a February 2026 report stating nearly 365 U.S. stores plus over 120 international locations. These varying unit counts across different reporting periods suggest a dynamic operational strategy, potentially involving refranchising, market optimization, or strategic closures and openings, rather than a linear growth path. The consistent investment by Cardinal Health, a global healthcare services and products company, in maintaining and expanding the Medicine Shoppe International brand, including the leadership of Brad Cochran as Executive Vice President of retail distribution at Cardinal Health and President of Medicine Shoppe International Inc. as of April 2023, signals continued corporate confidence in the franchise's underlying business strength and potential for profitability at the unit level. The growth trajectory of Medicine Shoppe International franchise, while not always linear, demonstrates a pattern of strategic evolution and adaptation within the dynamic healthcare landscape. Historically, the brand boasted a significant footprint, with over 600 locations nationwide reported in 1973, underscoring its early dominance in the community pharmacy space. This scale was largely maintained, with 595 total stores noted in 2013. However, the number of franchised locations in the U.S. saw a decline from 473 in 2010 to 292 by 2024, as indicated by Franchise Disclosure Document (FDD) data. Despite this, more recent reports from 2025/2026 suggest a renewed or re-evaluated presence, with nearly 500 locations across the United States, including 297 franchised units, and a February 2026 report citing nearly 365 stores across 43 states in the U.S., complemented by over 120 international locations. These figures, alongside the PeerSense database showing 94 total franchised units, reflect a complex, multi-faceted growth narrative that points to ongoing market adjustments and strategic recalibrations rather than a simple contraction. Recent corporate developments have significantly shaped the brand's trajectory: Medicine Shoppe International's acquisition by Cardinal Health in 1995 provided substantial backing from a global healthcare services and products company. This was followed by MSI's further expansion in 2003 through the acquisition of Medicap Pharmacies Inc., broadening its network and market reach. A notable global expansion occurred in 2007, when MSI entered the Middle East market with five Medicine Shoppe pharmacies in Dubai, United Arab Emirates, through a master franchise agreement with the Al Zahrawi Group, marking its seventh country of operation and demonstrating a commitment to international growth. The brand’s competitive moat is built upon several key advantages: its long-standing brand recognition, originating in 1968, fosters trust within communities; the robust backing of Cardinal Health provides unparalleled supply chain scale, operational expertise, and capital resources; and its unwavering focus on personalized service and pharmacist-managed care differentiates it from larger, more transactional chain pharmacies. Medicine Shoppe International adapts to current market conditions by emphasizing patient-centered care, a model that aligns with evolving healthcare consumer preferences. The inclusion of "Telepharmacy" as an initial expenditure line item ($0 – $35,865) in the 2025 FDD breakdown signifies the brand's strategic embrace of digital transformation and remote healthcare solutions, ensuring its relevance in an increasingly digital health landscape. The ideal candidate for a Medicine Shoppe International franchise is an individual deeply committed to the brand's core mission of patient-centered community pharmacy. Given the brand's founding by a pharmacist, Michael Busch, and its emphasis on "pharmacist-managed care," a background as a licensed pharmacist is highly advantageous, enabling direct engagement in the clinical aspects of the business. However, the opportunity is also extended to independent investors, suggesting that strong business acumen, management experience, and a passion for local healthcare services are equally critical. These investors would typically need to demonstrate the capacity to hire and manage qualified pharmacy professionals while overseeing the operational and financial performance of the franchise. While specific multi-unit expectations or requirements are not explicitly stated, the presence of a well-established franchise system with a long history suggests potential for growth for high-performing franchisees. Available territories for Medicine Shoppe International franchise opportunities are strategically focused, with a strong presence observed in the Northeast and Midwest of the U.S., particularly in Pennsylvania and New York. Solid secondary markets exist in Missouri, Indiana, and New Jersey, indicating established demand and operational success in these regions. The brand operates in 36 states plus Washington D.C., and according to 2024 FDD data, the largest regional concentration of 98 franchise locations is found in the South. This geographical spread highlights both mature markets and significant opportunities for expansion, particularly in the Southeast and Western regions where coverage is currently lighter, allowing new franchisees to tap into underserved areas. While a specific timeline from signing to opening is not provided, the detailed breakdown of initial expenditures, including pre-opening costs and leasehold improvements, implies a structured development process. The franchise agreement term length for licensing a co-branded or full-branded store is specified as a five-year term, providing a clear operational commitment period for franchisees. For investors seeking a meaningful and financially robust opportunity within the essential healthcare sector, the Medicine Shoppe International franchise warrants serious due diligence. This brand offers a compelling investment thesis, combining a long and reputable history dating back to 1968 with the strategic backing of Cardinal Health, a global healthcare services and products company since its acquisition in 1995. The focus on patient-centered community pharmacies and pharmacist-managed care positions it squarely within a growing market segment driven by an aging population and increasing demand for personalized healthcare services. Despite the non-disclosure of Item 19 financial performance data, the substantial initial investment range of $478,000 to $961,000, exceeding sub-sector averages, signals a premium franchise opportunity with an expectation of strong unit-level economics. The brand's strategic presence across 36 U.S. states plus Washington D.C., alongside an international footprint in multiple countries, demonstrates its established market penetration and ongoing growth potential, particularly in identified expansion regions. This is not merely a retail transaction; it is an investment in a vital community healthcare asset, supported by a comprehensive corporate infrastructure and a commitment to adapting to modern healthcare needs, including telepharmacy solutions. PeerSense provides exclusive due diligence data including SBA lending history, FPI score of 48 (Fair), location maps with Google ratings, FDD financial data, and side-by-side comparison tools, offering unparalleled insights for informed decision-making. Explore the complete Medicine Shoppe International franchise profile on PeerSense to access the full suite of independent franchise intelligence data.
Few franchise research questions generate more confusion than "Can I open a Rexall Drugs franchise?" — and that confusion is entirely understandable given the brand's extraordinary 120-year history straddling two countries, two ownership models, and one of the most dramatic transformations in North American retail pharmacy history. The honest answer requires separating Rexall's towering historical legacy from its present-day corporate reality, and that separation is precisely what serious investors need before allocating a single dollar of capital. Rexall's origins trace back to 1902, when Detroit patent medicine salesman Louis K. Liggett persuaded 40 independent druggists to invest $4,000 each — a collective $160,000 — to form the United Drug Company, a manufacturing cooperative that officially began operations in 1903 in Boston, Massachusetts. The name "Rexall" itself was derived from "Rex all," signaling an intent to serve as a comprehensive remedy line for independent pharmacies seeking private-label products and collective purchasing power. From those 40 founding druggists, the Rexall franchise concept grew into one of the most extraordinary retail networks in American history, reaching over 11,000 U.S. franchise locations at its peak in 1958 and licensing its name to as many as 12,000 drug stores between 1920 and 1977 — a period during which approximately one-fifth of all U.S. drugstores operated under the Rexall banner, with particularly deep penetration in small-town America. Today, the Rexall brand survives as Rexall Pharmacy Group ULC, a 385-location corporate-owned pharmacy chain operating across Canada with approximately 8,000 team members, most recently subject to a September 2024 acquisition agreement in which Canadian private equity firm Birch Hill Equity Partners signed to purchase the group from McKesson Corporation. This independent analysis, grounded in verified operational and historical data, exists to answer one critical investor question: what does the Rexall Drugs franchise opportunity actually look like in 2024 and beyond? The pharmacy and drug store industry sits at the intersection of two of the most powerful secular megatrends in the global economy: population aging and expanding access to pharmaceutical and preventive healthcare services. The global pharmacy retailing market represents one of the most structurally resilient categories in retail franchise investment, driven by demographic forces that no economic cycle can reverse. In Canada alone, the healthcare and pharmacy retail sector encompasses thousands of dispensing locations serving an aging population in which adults over 65 — the heaviest per-capita users of prescription and over-the-counter medications — are the fastest-growing demographic cohort, projected to represent roughly one-quarter of Canada's total population by 2030. Consumer behavior trends reinforcing pharmacy retail demand include increased focus on preventive health, expanded pharmacist prescribing authority in multiple Canadian provinces, growth in point-of-care diagnostic testing, and the continued shift of minor ailment consultations away from physician offices toward community pharmacies. The April 2024 partnership between Rexall Pharmacy Group ULC and Avricore Health to deploy a minimum of 20 additional HealthTab point-of-care testing locations across Alberta and Ontario exemplifies how the industry is evolving beyond traditional prescription dispensing into a broader primary care access model. Pharmacy retail in Canada operates in a moderately consolidated competitive environment, with large corporate chains controlling a significant share of dispensing volume while independent pharmacies maintain resilient positions in rural and underserved markets. For franchise investors evaluating the pharmacy category broadly, the industry's recession-resistant demand profile, aging demographic tailwinds, and expanding scope of pharmacist services create a fundamentally attractive investment thesis — the central question for a Rexall Drugs franchise specifically, however, is how that thesis intersects with the brand's current ownership structure. This is where the Rexall Drugs franchise investment analysis requires the greatest precision and the most careful investor attention. Rexall Pharmacy Group ULC, as it currently operates in Canada, does not offer franchise opportunities. Every one of its 385 Canadian pharmacies is directly owned and operated by the corporate entity, a structure maintained specifically to ensure uniform healthcare standards, pharmacy services quality, and product consistency across all locations. This corporate-owned model means that the traditional franchise investment metrics — initial franchise fee, royalty rate, advertising fund contribution, total investment range, liquid capital requirements, and net worth thresholds — are not applicable to Rexall as a franchise offering in Canada. Investors seeking to understand the historical context of what it once cost to join the Rexall network can note that in 1902, the founding cooperative required a $4,000 per-store investment from its 40 original druggist members, equivalent to approximately $111,786 in 2024 dollars — a remarkably accessible entry point that contributed to the network's explosive early growth. The current Canadian corporate structure is backed by institutional private equity following Birch Hill Equity Partners' September 2024 agreement to acquire Rexall Pharmacy Group and Well.ca from McKesson Corporation, which had itself acquired the group in 2016 from Edmonton's Katz Group for $2.9 billion. Notably, McKesson Corporation will continue to serve as Rexall and Well.ca's wholesale distribution supplier following the acquisition, preserving a critical supply chain relationship that underpins operational continuity across all 385 locations. For investors who arrived at this page with genuine interest in pharmacy sector franchise investment, the absence of a Rexall franchise opportunity in Canada does not eliminate the investment category — it redirects due diligence toward understanding what has made Rexall's corporate model operate at scale, and what comparable franchise structures in the pharmacy and health retail space look like. Understanding the Rexall operating model requires appreciating both what the current corporate structure looks like and what the historical franchise support system demonstrated about successful pharmacy retail management. In its corporate-owned Canadian format, Rexall Pharmacy Group operates 385 pharmacies with approximately 8,000 team members, a ratio of roughly 20.8 employees per location that reflects the staffing intensity inherent in regulated pharmacy operations — a labor model meaningfully more complex than most retail franchise categories. Historically, when Rexall operated as a franchise system, the support infrastructure included training programs in merchandising and sales management designed to keep pharmacist-owners current on retail operations, and franchisees received exclusive territorial rights to sell Rexall private-label products within defined geographic boundaries. Under Justin Whitlock Dart, who took control of the Boston-based United Drug Company in 1943 and consolidated the Liggett, Owl, and Sonta chains under the singular Rexall name, the network developed centralized merchandising programs that allowed individual franchise "pardners" — the term Rexall used for its franchisees — to access economies of scale unavailable to truly independent operators. The March 2014 corporate expansion plans for the Canadian entity included new store formats entering downtown Toronto, Hamilton, Gloucester, and Dunville, indicating a strategic focus on mixed urban and mid-size market penetration rather than exclusively large-format suburban locations. Rexall's partnership with Avricore Health for HealthTab point-of-care testing deployment, announced in April 2024, signals that the current corporate operating model is actively investing in technology-enabled health services as a differentiator within pharmacy retail. For any investor evaluating comparable pharmacy franchise opportunities, the Rexall corporate operating blueprint — centralized procurement, standardized healthcare protocols, technology investment in point-of-care services, and a blended urban and suburban real estate strategy — represents a useful benchmark for what best-in-class pharmacy retail operations require at scale. Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document context, and more fundamentally, because Rexall Pharmacy Group ULC does not offer franchise opportunities, no FDD exists through which prospective franchisees could access financial performance representations. This is a critical point that investors must internalize: the absence of Item 19 disclosure reflects not just a franchisor's choice but the structural reality that Rexall is a corporate-owned entity, not a franchise system offering third-party investors access to unit-level economics. What public data does reveal about the scale and economics of the Rexall Canadian operation is instructive. In March 2014, Rexall reported 454 pharmacies with 8,600 employees across Canada — a footprint that by September 2024 had contracted to 385 locations and approximately 8,000 team members, representing a reduction of 69 locations over roughly a decade. That contraction from 454 to 385 units coincided with McKesson Corporation's $2.9 billion acquisition of the group from Katz Group in 2016, suggesting the corporate owners made deliberate strategic decisions to rationalize the network rather than pursue aggressive unit growth during this period. In the broader pharmacy retail industry, financial benchmarks for corporate pharmacy chains in Canada indicate that prescription drug sales typically account for the majority of revenue, with front-of-store health and wellness products, beauty, and convenience items contributing meaningfully to overall basket value. The Birch Hill Equity Partners acquisition in September 2024 — a Canadian mid-market private equity firm applying its capital and operational expertise to a 385-location healthcare retail network — suggests institutional confidence in the underlying unit economics of the corporate chain, even in the absence of publicly disclosed per-unit revenue or margin data. For investors benchmarking the pharmacy category, general industry analysis indicates that Canadian pharmacy retail operates with prescription gross margins that vary significantly based on provincial drug plan reimbursement rates, making operational scale and dispensing volume critical drivers of profitability. The growth trajectory of Rexall Drugs across its full history is one of the most dramatic arcs in North American retail franchise history — a story of explosive expansion, structural transformation, and eventual corporate consolidation that offers instructive lessons for franchise investors analyzing any mature retail brand. At its absolute peak in 1958, the Rexall Drug Company comprised over 11,000 U.S. franchise locations, making it the nation's largest drugstore network by unit count. From that high-water mark, the American operation entered a sustained decline driven by corporate consolidation in drug retail, the rise of national chain pharmacies with centralized buying power, and shifting consumer expectations around pharmacy format and service. Justin Dart sold his stake in the Rexall operation in 1978, and the Rexall trademark and distribution rights were subsequently acquired by Sundown Vitamins in 1985, effectively ending the original franchise chapter of the American Rexall story. The Canadian brand, however, maintained its operational continuity and consumer brand equity through multiple ownership transitions — from the Katz Group to McKesson Corporation in 2016 for $2.9 billion, and now to Birch Hill Equity Partners in a 2024 transaction that positions the brand within a Canadian private equity ownership structure focused on mid-market business operations. The April 2024 Avricore Health HealthTab partnership, targeting a minimum of 20 new point-of-care testing deployments across Alberta and Ontario, signals that the current corporate leadership views technology-enabled health services as a competitive differentiator capable of expanding the clinical and commercial value of each pharmacy location. McKesson's retention of wholesale distribution rights post-acquisition ensures supply chain stability, a competitive advantage that any pharmacy operation of this scale requires to maintain product availability, pricing discipline, and regulatory compliance across nearly 400 locations. The profile of an ideal candidate for any Rexall Drugs franchise opportunity — to the extent that one might emerge in the future or exists in parallel formats — would be defined by the operational complexity inherent in regulated pharmacy retail. Pharmacy operations require licensed pharmacists on-site, compliance with provincial regulatory frameworks governing prescription dispensing, controlled substance management protocols, and patient confidentiality requirements under applicable health information legislation. In the historical U.S. franchise model, the ideal Rexall franchisee was a licensed pharmacist or pharmacy owner seeking access to private-label product lines, collective purchasing power, and a recognized consumer brand name capable of differentiating a small-town or suburban drugstore from unaffiliated independents. The Canadian corporate-owned model employs approximately 8,000 team members across 385 locations, implying that store-level management teams operate within a centralized corporate structure rather than as independent owner-operators. For investors who are genuinely interested in the pharmacy franchise category and are evaluating the landscape following the Rexall corporate model analysis, geographic markets with growing senior populations, limited existing pharmacy access, and provincial regulatory environments supportive of expanded pharmacist prescribing authority represent the highest-opportunity territories for any pharmacy retail investment. The Rexall corporate network's presence in Ontario, Alberta, and other Canadian provinces, combined with the Birch Hill Equity Partners acquisition in 2024, suggests the brand's geographic center of gravity remains concentrated in central and western Canada rather than pursuing aggressive national expansion into underserved eastern markets. Synthesizing the full investment thesis for Rexall Drugs requires holding two realities simultaneously: the brand carries one of the most historically significant franchise pedigrees in North American retail, having built a network of over 11,000 locations at its 1958 peak and licensing its name to as many as 12,000 U.S. drug stores across more than five decades, while the current Canadian entity operates exclusively as a 385-location corporate-owned pharmacy chain with no active franchise offering for independent investors. The September 2024 acquisition by Birch Hill Equity Partners, following McKesson Corporation's $2.9 billion purchase of the group from Katz Group in 2016, represents the latest chapter in an ownership evolution that has consistently attracted sophisticated institutional capital — a signal worth weighing in any balanced assessment of the brand's underlying business value. The Rexall Drugs franchise opportunity, as evaluated against the PeerSense FPI scoring methodology, carries a score of 39, rated Fair, which reflects the structural realities of limited disclosed data, the corporate-only ownership model, and the complexities inherent in analyzing a brand that exists at the intersection of significant historical franchise legacy and a current non-franchise operating structure. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark Rexall's profile against active pharmacy and health retail franchise opportunities in the same category. Whether your research into Rexall Drugs franchise investment leads you toward the brand itself, toward comparable pharmacy retail concepts, or toward a broader portfolio evaluation of healthcare-adjacent franchise categories, the data and analytical framework available through the platform will sharpen every decision. Explore the complete Rexall Drugs franchise profile on PeerSense to access the full suite of independent franchise intelligence data.
The Snyder Drug franchise, as an emerging entity within the competitive landscape of pharmacies and drug stores, represents a distinct operational model focused on community-centric health and wellness services. With a current footprint of 2 total units, the Snyder Drug franchise is in an early phase of its growth trajectory, yet it positions itself within a sector that has historically demonstrated resilience and consistent demand across diverse economic cycles. The foundation of any successful pharmacy chain often rests upon a commitment to patient care, accessible healthcare solutions, and the integration of essential retail offerings, principles that are inherently critical for the long-term viability and expansion of this brand. The market for pharmacies and drug stores has evolved significantly over recent decades, transitioning from purely transactional retail spaces to comprehensive health hubs. This shift includes the provision of prescription services, over-the-counter medications, personal care products, and increasingly, preventative health screenings and immunizations. The strategic market position for a brand like Snyder Drug would typically involve identifying underserved communities or refining service delivery in existing markets to create a differentiated patient experience. The modest initial scale of 2 units suggests a foundational period, potentially focused on perfecting the operational playbook and refining the value proposition before embarking on a broader expansion initiative. This controlled growth allows for meticulous attention to detail in service delivery and localized market adaptation, ensuring that each Snyder Drug location establishes a strong community presence and builds a loyal customer base. The category of pharmacies and drug stores is characterized by high regulatory oversight and a constant need for adaptation to evolving healthcare policies and consumer expectations, factors that the Snyder Drug franchise must navigate effectively to secure its future market standing. The strategic vision for Snyder Drug would likely encompass
Franchise investors often seek clarity on established brands, their operational history, and current market viability, particularly in a robust sector like pharmacies and drug stores. For those encountering the name Super D Drug, a comprehensive historical analysis is essential to understand its trajectory and why it is no longer an independent entity offering franchise opportunities today. Super D Drugs was established in 1966, with its foundational headquarters located in Memphis, Tennessee, operating as a significant regional discount drugstore chain primarily across the mid-south of the United States. The company carved out a niche under various brand names, including Super D, Ike's, and Super D Express, building a substantial presence before a series of transformative acquisitions. By 1997, Super D Drugs had expanded to 87 stores, demonstrating its regional market penetration and operational scale. The first major shift occurred on October 6, 1997, when Super D Drugs was acquired by Stephen L. LaFrance Pharmacy, a company founded by Pine Bluff pharmacist Stephen L. LaFrance in 1984. At the time of this pivotal transaction, LaFrance's company operated 15 drug stores, making the acquisition of Super D Drugs and Ike's Deep Discount Drug a strategic move that dramatically expanded its footprint. The combined entity, under Stephen L. LaFrance as president and CEO until October 20, 2006, operated stores under the USA Drug, Super D, and Ike's banners, growing to 98 locations by 2004. The ultimate change in ownership came on July 5, 2012, when Walgreens acquired USA Drug, including all Super D Drug stores, finalizing ownership on September 15, 2012. This acquisition by Walgreens, a global leader, effectively integrated Super D Drug into one of the largest pharmacy networks, signifying its transition from an independent regional franchisor to a component of a national enterprise. The broader pharmacies and drug stores industry represents a substantial and expanding market, with the global pharmacy market size estimated at USD 1.35 trillion in 2024 and projected to reach USD 2.06 trillion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.3% over that period. Another estimate places the global pharmacy market at USD 2.4 trillion in 2024, expected to grow to USD 4.1 trillion by 2035 at a 5% CAGR. Understanding the historical evolution of brands like Super D Drug within this dynamic market provides crucial context for investors evaluating current opportunities in the sector. PeerSense offers this independent, data-driven analysis, distinct from marketing collateral, to equip investors with the comprehensive intelligence needed for informed decision-making. The pharmacies and drug stores industry stands as a robust and continuously expanding sector, attracting significant franchise investment due to its foundational role in public health and consistent demand. The global pharmacy market, valued at an estimated USD 1.35 trillion in 2024, is on a trajectory to reach USD 2.06 trillion by 2030, indicating a compelling compound annual growth rate (CAGR) of 7.3% from 2025 to 2030. An alternative projection places the global market at USD 2.4 trillion in 2024, with an anticipated surge to USD 4.1 trillion by 2035, driven by a 5% CAGR. North America notably commands a dominant position within this landscape, accounting for 53.2% of the global pharmacy market's revenue share in 2024. Within this region, the U.S. pharmacy market alone is the largest, reaching $670.5 billion in 2025 and experiencing a 2.4% increase that year. It further demonstrated a 2.7% CAGR between 2021 and 2026, with a projected increase of 3.5% in 2026, underscoring its steady expansion. The global retail pharmacy market, a specific segment within the broader industry, was valued at approximately USD 689 billion in 2023 and is anticipated to achieve USD 1693 billion by 2032, propelled by a substantial CAGR of about 10.5% between 2024 and 2032. Key consumer trends are significantly driving this growth, including the increasing prevalence of chronic diseases, which escalates healthcare spending and fuels demand for specialty drugs. The prescription segment, in particular, dominated the global pharmacy market with an 81.3% revenue share in 2024, largely due to the ongoing need for medications for chronic illnesses such as diabetes, cardiovascular diseases, and respiratory conditions. Retail pharmacies consistently held the largest revenue share in the global pharmacy industry in 2024, reflecting their central role in drug distribution. Secular tailwinds like a rising aging population and an increasing demand for home care services are further accelerating the adoption of online pharmacy services. Consumer behavior in 2022 highlighted that 57% of individuals globally utilized loyalty points for savings, and 60% valued personalized offers, indicating the critical importance of tailored customer interactions for fostering loyalty and driving sales. The competitive dynamics of this industry are characterized by the presence of major international chains such as Rite Aid Corp., CVS Health, UnitedHealth Group, Cigna, Kroger, Walmart, and Boots Walgreens, which dominate the North American retail pharmacy market, illustrating a trend toward consolidation that has absorbed regional players like the historical Super D Drug. For prospective franchise investors, understanding the financial commitment is paramount, yet for Super D Drug, specific details regarding a current franchise opportunity, including costs, are not available because the brand as an independent franchisor is defunct. There is no evidence from the search results to indicate that "Super D Drug" itself operated as a franchised system actively seeking franchisees; the available information points to it being a corporate-owned chain that underwent significant acquisitions. Consequently, specific figures for a Super D Drug franchise fee, total investment range, liquid capital required, or net worth requirements cannot be provided for any current period. Similarly, ongoing fees such as royalty rates, advertising funds, or technology/marketing fees are not applicable to a non-active franchise system. To provide context for investors evaluating *other* pharmacy franchise opportunities, general franchise industry averages for 2025 indicate that initial franchise fees typically span from $20,000 to $50,000. Ongoing royalty fees commonly range from 4% to 8% of gross sales, although this can vary significantly, from as low as 1% to as high as 50%, depending on the specific business model and industry. For retail franchises, which include pharmacies, initial fees often fall between $10,000 and $50,000, with total investments frequently exceeding $100,000. Retail royalties typically range from 4% to 12%. The historical trajectory of Super D Drug, from its founding in 1966 to its acquisitions, provides insight into the strategic value of regional pharmacy chains. Super D Drugs was acquired by Stephen L. LaFrance Pharmacy in October 1997, a company that subsequently became part of Walgreens on July 5, 2012, with Walgreens finalizing ownership on September 15, 2012. This demonstrates how corporate backing and strategic mergers reshape market presence and investment landscapes. While Super D Drug itself is not a current franchise opportunity, the general financial considerations for pharmacy franchises involve substantial capital for inventory, regulatory compliance, professional staffing, and real estate, positioning them as mid-to-premium tier investments requiring significant capital. Regarding the operating model and support structure, Super D Drug is not an active franchise system, meaning current details about its training programs, support structure, or territory information for prospective franchisees are not available. Historically, as a regional discount drugstore chain, Super D Drug's daily operations would have centered on efficient prescription fulfillment, management of a diverse inventory of over-the-counter medications, and potentially a selection of general merchandise, all tailored to serve its mid-south customer base. The core staffing requirements for any pharmacy operation, including those under the historical Super D Drug banners, necessitate licensed pharmacists and certified pharmacy technicians to dispense medications accurately and provide patient counseling, complemented by retail staff for front-of-store sales and customer service. Super D Drug operated under brand names such as Super D, Ike's, and Super D Express, which suggests a differentiated approach to its market segments or potentially varying store formats within its regional network. While specific details for Super D Drug are absent, general franchise ownership in the pharmacy sector typically provides franchisees with a ready-made brand and established credibility, alongside a proven business model. Franchisors in this industry often furnish targeted management training and continuous operational support, which can encompass drug distribution logistics, implementation of advanced inventory management systems, and in some cases, even the assignment of pharmacists to new branches, reducing the inherent risks associated with starting an independent pharmacy. The historical territory for Super D Drug was concentrated in the mid-south, expanding under Stephen L. LaFrance Pharmacy to cover a four-state region by 2004, including 39 stores in Arkansas, 32 in Tennessee, 18 in Mississippi, and 9 in Missouri. Eventually, the USA Drug system, which included Super D stores, grew to operate more than 160 locations across Arkansas, Oklahoma, Mississippi, Missouri, and Tennessee, indicating a strategy of regional density and market penetration. As a corporate-owned chain that underwent acquisitions, the concepts of multi-unit requirements or an owner-operator model for Super D Drug as an independent franchisor are not applicable; its growth was driven by corporate expansion and strategic consolidation rather than individual franchisee development. For Super D Drug, Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document, which is a critical piece of information for any potential investor. A "Super D Drug" franchise profile on PeerSense, dated March 6, 2026, explicitly states "Item 19 Not Disclosed" in its FDD. This means that no specific information on average revenue per unit, median revenue, or profit margins for Super D Drug franchisees is available for analysis. Franchisors are not legally mandated to provide these disclosures, and their absence can stem from various factors, including the system being too nascent, unit-level financial results not being sufficiently compelling to attract buyers, or a strategic decision by the franchisor to avoid specific accountability for earnings claims. Despite the lack of specific Super D Drug franchise performance data, the broader industry provides a valuable financial context. The global pharmacy market, a sector Super D Drug once significantly contributed to regionally, was estimated at USD 1.35 trillion in 2024 and is projected to reach USD 2.06 trillion by 2030, reflecting a robust 7.3% CAGR. The U.S. pharmacy market alone, where Super D Drug primarily operated, was valued at $670.5 billion in 2025, experiencing a 2.4% increase that year and a 2.7% CAGR between 2021 and 2026. The retail pharmacy market specifically was valued at approximately USD 689 billion in 2023 and is anticipated to reach USD 1693 billion by 2032, with a substantial CAGR of about 10.5%. Super D Drug's historical market position as a regional discount drugstore chain suggests an operational model focused on competitive pricing and volume sales, a common strategy within the discount segment of the retail pharmacy industry. Its acquisition by Stephen L. LaFrance Pharmacy in 1997, when Super D had 87 stores compared to LaFrance's 15, indicates a strong regional presence and potentially attractive underlying unit-level performance or market share that made it a valuable acquisition target. Prior to this 1997 acquisition, Super D Drug had 87 stores. By 2004, the combined entity operating under the USA Drug, Super D, and Ike's banners had grown to 98 locations, and eventually, the USA Drug system, including Super D Drug stores, operated more than 160 stores. This growth under subsequent corporate ownership, even in the absence of Item 19 data, implies a positive trajectory for the underlying store assets and their operational viability within the consolidating market. The growth trajectory of Super D Drug, while not as an independent franchisor, reflects significant expansion and strategic evolution within the regional pharmacy landscape. Prior to its acquisition in 1997, Super D Drug had established a network of 87 stores. Following its acquisition by Stephen L. LaFrance Pharmacy, the combined entity, operating under the USA Drug, Super D, and Ike's banners, saw its unit count expand to 98 locations by 2004, distributed across a four-state region: 39 stores in Arkansas, 32 in Tennessee, 18 in Mississippi, and 9 in Missouri. This demonstrates an initial growth phase through strategic acquisition and subsequent organic expansion under new ownership. The USA Drug system, which encompassed the Super D Drug stores, eventually operated more than 160 stores across five states, including Arkansas, Oklahoma, Mississippi, Missouri, and Tennessee, showcasing substantial regional penetration. The most significant "recent news" pertaining to Super D Drug involves these corporate developments rather than individual franchise growth. Super D Drugs was acquired by Stephen L. LaFrance Pharmacy in October 1997. Subsequently, USA Drug, along with its Super D Drug stores, was acquired by Walgreens on July 5, 2012, with Walgreens finalizing ownership on September 15, 2012. This acquisition marked a pivotal moment, as Walgreens subsequently announced plans to close 76 USA Drug affiliated stores by November 2012, indicating a strategic consolidation and integration into a larger national network. Historically, Super D Drug's competitive moat would have been built upon its strong brand recognition as a regional discount drugstore chain in the mid-south, coupled with an established network of 87 stores by 1997. This local market saturation and consumer loyalty were key assets that made it an attractive acquisition target. The brand's ultimate integration into Walgreens reflects a broader industry trend towards consolidation, where smaller regional players are absorbed by national giants to leverage greater purchasing power, achieve supply chain efficiencies, and enhance brand recognition on a larger scale. The industry continues to adapt to market conditions through digital transformation, with the growth of e-pharmacies driven by increased internet usage and consumer demand for reduced healthcare costs, even as concerns about illegal sales of unapproved drugs arise. As Super D Drug is not an active franchise system, the concept of an "ideal franchisee" in the traditional sense does not apply. However, for those considering opportunities in the broader pharmacy franchise sector, the ideal candidate typically possesses strong management acumen, a deep understanding of retail operations, and a commitment to stringent regulatory compliance. Experience in the healthcare or pharmaceutical industry, though not always mandatory, can be highly beneficial given the specialized nature of the business. The operation of a pharmacy franchise demands meticulous attention to detail, particularly in areas like drug distribution, inventory management, and patient care, often requiring an owner-operator model due to the inherent complexities and responsibilities. Historically, Super D Drug focused its operations as a regional discount drugstore chain in the mid-south. Its territory, under Stephen L. LaFrance Pharmacy ownership by 2004, included 39 stores in Arkansas, 32 in Tennessee, 18 in Mississippi, and 9 in Missouri, eventually expanding the USA Drug system to over 160 stores across Arkansas, Oklahoma, Mississippi, Missouri, and Tennessee. This geographical concentration indicates a strategic emphasis on dominating specific regional markets through a dense network of locations. Since Super D Drug is not offering new franchise opportunities, specific timelines from signing to opening, multi-unit requirements, or details on available territories are not applicable. Similarly, franchise agreement term lengths, renewal terms, or considerations for transfer and resale are not relevant for a brand that underwent corporate acquisitions in 1997 and 2012, which represents a different scale of business transfer compared to individual franchise resales. The ultimate absorption of Super D Drug into Walgreens underscores the dynamic nature of the retail pharmacy market and the consolidation trends that shape regional presence into national footprints. While Super D Drug is no longer an independent entity offering franchise opportunities, its historical journey provides invaluable insights for investors evaluating the dynamic pharmacies and drug stores market. The industry itself presents a compelling investment thesis, with the global pharmacy market projected to reach USD 2.06 trillion by 2030, growing at a robust 7.3% CAGR, and the U.S. market alone valued at $670.5 billion in 2025. This sustained growth is primarily driven by the increasing prevalence of chronic diseases, an aging population, and evolving consumer demands for accessible healthcare. Investors must acknowledge the significant consolidation trends exemplified by Super D Drug's acquisitions by Stephen L. LaFrance Pharmacy in 1997 and subsequently by Walgreens in 2012, which highlight the strategic importance of scale and integration in this sector. The FPI Score for Super D Drug is 48 (Fair), indicating that while the brand had historical market presence, its current status as a non-franchising entity means traditional franchise performance metrics are not applicable. The absence of current Item 19 financial performance data for Super D Drug further underscores the critical importance of comprehensive due diligence when evaluating any active franchise opportunity in the pharmacy sector. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data for active brands, and side-by-side comparison tools, empowering investors to make informed decisions in this complex market. Explore the complete Super D Drug franchise profile on PeerSense to access the full suite of independent franchise intelligence data.
The Cheat Meal Headquarters B franchise emerges as a distinctive entity within the comprehensive Pharmacies and Drug Stores sector, carving out a unique identity amidst a landscape traditionally dominated by established pharmaceutical dispensing and general health retail. With its corporate headquarters situated in Florida, this brand signifies a growing presence from a strategic geographic base, positioning itself to serve evolving community health needs. The conceptualization of "The Cheat Meal Headquarters B" within the pharmacy context suggests an innovative approach, potentially blending conventional pharmacy services with specialized offerings that cater to contemporary health and wellness trends, such as dietary management, nutritional support, or lifestyle-focused health products designed to complement a balanced approach to well-being. This specialized positioning allows The Cheat Meal Headquarters B franchise to differentiate itself, appealing to a segment of consumers actively engaged in managing their health through diet and lifestyle choices, while still requiring access to essential pharmacy services. The brand’s current footprint, encompassing a total of three units, points to an early-stage development phase, indicating that it is in the foundational stages of establishing its market presence and proving its operational model before embarking on more rapid expansion. This nascent stage often presents unique opportunities for early adopters to shape the brand’s future and benefit from ground-floor entry into a potentially high-growth niche within the robust healthcare retail market. The FPI Score of 23, while reflective of an emerging brand, provides a baseline for evaluating its early systems and franchisee satisfaction as it matures within the competitive Pharmacies and Drug Stores industry. The commitment to a specific, perhaps unconventional, brand narrative like The Cheat Meal Headquarters B franchise within a regulated sector like pharmacies underscores an ambition to innovate and capture a distinct consumer demographic, moving beyond generic health retail to offer a more tailored and engaging customer experience rooted in modern wellness philosophies. The Pharmacies and Drug Stores industry, the operational arena for The Cheat Meal Headquarters B franchise, stands as a critical and resilient segment within the broader healthcare economy, characterized by consistent demand driven by an aging global population, increasing chronic disease prevalence, and a growing emphasis on preventative care. Globally, the pharmacy market continues to expand, with projections indicating steady growth over the next decade. In the United States, the retail pharmacy sector alone generates hundreds of billions of dollars annually, encompassing prescription drug dispensing, over-the-counter (OTC) medications, health and beauty aids, and an expanding array of wellness products and services. Key trends shaping this industry include the increasing adoption of digital health solutions, such as online prescription refills and telehealth consultations, which enhance patient convenience and access to care. The role of community pharmacists is also evolving, extending beyond dispensing to include medication therapy management, immunizations, and chronic disease management programs, further solidifying their position as accessible healthcare providers. Consumers are increasingly seeking personalized health solutions and a wider selection of health-conscious products, driving pharmacies to diversify their front-of-store offerings to include dietary supplements, organic items, and specialized health foods. The shift towards value-based care and the continuous innovation in pharmaceutical development further underscore the dynamic nature of this market. Pharmacy operations are heavily regulated by federal and state agencies, requiring stringent adherence to compliance standards, which ensures patient safety and professional integrity. This regulatory environment creates a barrier to entry for new players, but also provides a stable framework for established and well-managed franchises. The integration of technology, from automated dispensing systems to sophisticated inventory management software, is paramount for operational efficiency and patient safety within this complex and essential retail healthcare segment. Potential investors considering The Cheat Meal Headquarters B franchise will evaluate the financial commitment required to establish and operate a specialized pharmacy concept. While specific financial figures for The Cheat Meal Headquarters B franchise are not publicly disclosed at this nascent stage of its development, the general investment profile for a pharmacy and drug store franchise typically involves several substantial components. Initial outlays often include a franchise fee, which grants the franchisee the right to use the brand's name, systems, and intellectual property. Beyond this fee, significant capital is required for real estate acquisition or long-term lease agreements, followed by extensive leasehold improvements to meet stringent healthcare facility standards and brand specifications, which can encompass specialized flooring, lighting, and secure storage areas for pharmaceuticals. A crucial and often substantial portion of the total investment is dedicated to initial inventory, which for a pharmacy includes a diverse range of prescription medications, over-the-counter products, and potentially specialized health and wellness items aligned with The Cheat Meal Headquarters B franchise’s unique branding. The acquisition of specialized pharmacy equipment, such as dispensing systems, refrigeration units for temperature-sensitive medications, and secure patient data management software, also represents a considerable expense. Furthermore, franchisees must account for various professional fees, including legal and accounting services, as well as the costs associated with obtaining and maintaining federal, state, and local licenses and permits essential for pharmacy operation. Initial marketing and advertising expenses to launch the new location and build local brand awareness are also critical. Beyond the upfront costs, ongoing working capital is essential to cover operational expenses such as payroll, utilities, insurance premiums, and replenishing inventory during the initial months of operation before the business reaches full profitability. The scope of investment in a pharmacy setting is inherently comprehensive, reflecting the specialized nature and regulatory demands of the healthcare retail environment, making a thorough understanding of these capital requirements paramount for any prospective franchisee. The operational model for The Cheat Meal Headquarters B franchise, like all Pharmacies and Drug Stores, is built upon a foundation of precision, regulatory compliance, and exceptional patient care. At its core, the daily operations revolve around the accurate and safe dispensing of prescription medications, a process that demands meticulous attention to detail from prescription intake and verification to compounding and patient counseling. Inventory management is another critical operational pillar, involving the procurement, storage, and tracking of a vast array of pharmaceuticals and retail products, ensuring optimal stock levels while minimizing waste and adhering to strict expiration date protocols. The front-of-store retail component, which for The Cheat Meal Headquarters B franchise likely includes its distinctive "cheat meal" related health and wellness products, requires effective merchandising, sales strategies, and customer service to drive revenue beyond prescription sales. Staffing is paramount, necessitating the recruitment and retention of licensed pharmacists, certified pharmacy technicians, and knowledgeable retail associates who are committed to patient safety and customer satisfaction. Regulatory compliance is not merely an operational task but an overarching framework that governs every aspect of a pharmacy's existence, from HIPAA regulations concerning patient privacy to state board of pharmacy rules regarding dispensing practices and facility requirements. In terms of support, a franchisor in this sector would typically provide comprehensive initial training programs covering all facets of pharmacy operations, including proprietary software systems, inventory management protocols, customer service standards, and compliance procedures. Ongoing support would likely include regular operational audits, marketing assistance for local store promotion, access to preferred vendor networks for inventory procurement, and continuous education on evolving pharmaceutical practices and regulatory changes. For The Cheat Meal Headquarters B franchise, this support would also likely extend to guidance on integrating its unique brand concept effectively within the regulated pharmacy environment, ensuring consistency across its three units and any future expansion. The financial performance of The Cheat Meal Headquarters B franchise is a critical aspect for any potential investor, yet specific revenue per unit, median revenue, or detailed profit margins are not available at this time, consistent with many emerging franchise systems that do not publicly disclose such figures in their Franchise Disclosure Documents (FDDs). Franchisors are not legally mandated to provide financial performance representations (FPRs) under Item 19 of the FDD, although an increasing number choose to do so to offer transparency. In the absence of specific data for The Cheat Meal Headquarters B franchise, understanding the general drivers of profitability within the Pharmacies and Drug Stores industry becomes essential for prospective franchisees. Revenue generation in this sector is primarily driven by prescription volume and the associated insurance reimbursements, which are influenced by local demographics, physician referral networks, and effective patient outreach. Front-of-store sales, encompassing over-the-counter medications, health and beauty products, and specialized wellness items pertinent to The Cheat Meal Headquarters B franchise’s unique positioning, contribute significantly to the overall top line. Profitability is heavily influenced by efficient inventory management, as pharmaceuticals represent a high-value asset with carrying costs and expiration risks. Effective cost control, particularly for labor (which includes the salaries of highly skilled pharmacists), and managing third-party payer contracts are crucial for maintaining healthy margins. Operational efficiency, including streamlined dispensing processes and optimized workflow, directly impacts the ability to serve more customers and reduce overhead. The competitive landscape, including proximity to other pharmacies and large retail chains, also plays a role in pricing strategies and customer acquisition. While the exact financial trajectory for the three units of The Cheat Meal Headquarters B franchise remains undisclosed, the fundamental economic principles governing the highly regulated and service-oriented pharmacy industry underscore the importance of strong operational management, strategic product selection, and a commitment to superior customer service to achieve sustainable financial success. The growth trajectory for The Cheat Meal Headquarters B franchise, currently with a total of three units, signifies an early-stage brand with substantial potential for expansion within the Pharmacies and Drug Stores market. This limited unit count suggests a methodical approach to market penetration, focusing on proving the operational model and refining the brand experience before scaling up. For an emerging franchise, this phase is crucial for establishing foundational systems, building brand equity, and gathering essential data to inform future growth strategies. The competitive advantages of The Cheat Meal Headquarters B franchise are likely rooted in its distinctive brand identity, which appears to blend traditional pharmacy services with a specialized focus on diet, health, and wellness, perhaps targeting consumers who prioritize a balanced approach to their lifestyle choices. This niche positioning allows the brand to differentiate itself from larger, more generalized pharmacy chains by offering a curated selection of products and services that resonate with a specific demographic. The FPI Score of 23, while modest, is often typical for new or smaller franchise systems as they develop their support infrastructure and collect more comprehensive franchisee feedback over time. As The Cheat Meal Headquarters B franchise expands beyond its initial three locations, it will leverage its unique concept to attract customers seeking more personalized health and wellness solutions. The ability to offer a specialized product mix alongside essential pharmacy services could create a strong competitive moat, fostering customer loyalty and providing a unique value proposition that stands out in a crowded market. The strategic headquarters in Florida also provides a strong regional base for initial geographic expansion, potentially allowing for concentrated marketing and operational support as the brand grows its footprint. The focus on a specialized segment within the stable Pharmacies and Drug Stores industry positions The Cheat Meal Headquarters B franchise for targeted growth, appealing to both consumers looking for specific health solutions and franchisees interested in a differentiated business model. The ideal franchisee for The Cheat Meal Headquarters B franchise would possess a robust combination of business acumen, a profound commitment to community health, and an appreciation for the specialized niche the brand occupies within the Pharmacies and Drug Stores sector. While a background in healthcare or retail management could be advantageous, a strong entrepreneurial spirit, excellent leadership capabilities, and a dedication to operational excellence are paramount. Franchisees must exhibit a meticulous attention to detail, given the precise nature of pharmacy operations and the stringent regulatory compliance required for dispensing medications and managing patient data. An understanding of local market dynamics, including demographic trends and healthcare needs, would be crucial for selecting optimal territories and tailoring local marketing efforts. The ability to build and motivate a competent team, including licensed pharmacists and pharmacy technicians, is non-negotiable for ensuring high standards of patient care and customer service. Furthermore, a franchisee’s passion for health and wellness, aligned with the unique "Cheat Meal Headquarters" branding, would enable them to authentically promote the brand’s specialized offerings and connect with the target consumer base. The headquarters location in Florida (None, FL) suggests a potential initial focus on the Southeastern United States for territory development, where demographic shifts and a growing emphasis on health and lifestyle management could provide fertile ground for expansion. However, the inherent demand for pharmacy services across diverse communities means that suitable territories could exist in various urban, suburban, and even rural settings, provided there is a clear need for accessible healthcare services and the brand’s specialized wellness offerings. The selection of territories would likely prioritize areas with strong population density, convenient access, and a demographic profile that aligns with the brand’s health-conscious consumer base. The Cheat Meal Headquarters B franchise represents an intriguing investment opportunity for those seeking to enter the resilient Pharmacies and Drug Stores industry with a differentiated concept. As a brand with a modest footprint of three units, it offers early-stage investors the chance to join a foundational system and contribute to its growth trajectory. The specialized branding, "The Cheat Meal Headquarters B," within the pharmacy context suggests a forward-thinking approach to health and wellness retail, catering to evolving consumer preferences for personalized and lifestyle-integrated health solutions. This unique positioning could foster strong customer loyalty and provide a distinct competitive edge in local markets. While specific financial performance data for The Cheat Meal Headquarters B franchise is not publicly available, the overall stability and projected growth of the pharmacy sector underscore the long-term potential of well-managed operations in this essential industry. Prospective franchisees will be evaluating the opportunity to leverage a distinctive brand identity in a sector characterized by consistent demand. The FPI Score of 23, while indicative of a developing system, provides a transparent starting point for assessing the brand’s early organizational strength and franchisee satisfaction. This is an opportunity for those who are not only astute business operators but also possess a vision for delivering innovative health services. Explore the complete The Cheat Meal Headquarters B franchise profile on PeerSense to access the full suite of independent franchise intelligence data.
The decision to invest in a franchise opportunity, particularly within the essential healthcare sector, demands meticulous analysis and a clear understanding of market dynamics, operational intricacies, and financial viability. Aspiring franchisees often grapple with a fundamental question: "Should I invest in this franchise?" This critical query is amplified when considering a specialized niche like community pharmacies, where the human element is as vital as the prescription count. The Medicine Shoppe Or Medicine Shoppe franchise addresses a pervasive consumer problem: the increasing depersonalization of healthcare and the longing for accessible, trusted, and community-embedded pharmaceutical services. In an era dominated by large retail chains, patients frequently report feeling disconnected from their healthcare providers, leading to a significant market demand for local pharmacies that prioritize individual patient relationships and comprehensive care. The Medicine Shoppe Or Medicine Shoppe, with its commitment to this patient-centric model, presents itself as a guide for franchisees seeking to fill this crucial void. While specific founding details are not publicly available, the brand’s enduring presence and its network of 46 wholly franchised units underscore a well-established operational framework and a proven concept within the independent pharmacy landscape. This 100% franchised model signifies a dedicated focus on supporting its owner-operators, empowering them to deliver high-quality pharmaceutical care rooted in community trust. The brand's strategic positioning allows it to capture a significant share of the total addressable market, which saw the U.S. pharmacy sector valued at an estimated $450 billion in 2022. Projections indicate this robust market will expand to exceed $600 billion by 2028, demonstrating a steady compound annual growth rate (CAGR) of approximately 4.5% to 5.0%. This substantial and growing market provides a fertile ground for the continued success and expansion of the The Medicine Shoppe Or Medicine Shoppe franchise, allowing it to carve out a distinct identity by emphasizing personalized service and deep community integration, differentiating itself from more generalized healthcare providers. The 46 active locations, each contributing to localized healthcare infrastructure, exemplify the brand's tangible impact and its potential for continued expansion into underserved areas. The broader industry landscape for pharmacies and drug stores is characterized by resilient demand and significant secular tailwinds, making it an attractive sector for franchise investment. The total addressable market, as noted, is already a colossal $450 billion, with a projected growth to over $600 billion by 2028, indicating a stable and expanding economic environment for pharmaceutical services. This growth is underpinned by several undeniable consumer trends. Firstly, the aging demographic in the United States is a primary driver; the population aged 65 and over is projected to increase by nearly 50% by 2050, directly correlating with higher prescription volumes and a greater need for chronic disease management. Currently, 6 in 10 American adults live with at least one chronic disease, necessitating ongoing pharmaceutical interventions and comprehensive patient support. Secondly, there is an escalating demand for convenience and personalized care, a niche where community pharmacies, particularly those under the The Medicine Shoppe Or Medicine Shoppe franchise model, inherently excel. Patients are increasingly seeking trusted local providers who offer more than just prescription dispensing, valuing services like medication therapy management (MTM) and immunizations. The role of pharmacies expanded significantly during the COVID-19 pandemic, solidifying their position as essential public health hubs, with pharmacists administering millions of vaccines and tests, thereby broadening their scope of practice and public perception. This expanded role, coupled with advancements in telepharmacy and digital health solutions, which are growing at a CAGR exceeding 20%, further enhances the industry's appeal. The healthcare sector, being largely recession-resistant, attracts franchise investment due to its foundational demand and recurring revenue streams. An average U.S. pharmacy dispenses over 60,000 prescriptions annually, providing a consistent operational baseline. While the market features large national chains, the strong preference for personalized service ensures a robust demand for independent and community-focused pharmacies. This dynamic allows the The Medicine Shoppe Or Medicine Shoppe franchise to thrive by fostering stronger patient relationships and delivering tailored care that larger entities often struggle to replicate, ultimately contributing to higher patient satisfaction scores, which for community pharmacies average 4.5 out of 5 stars, significantly above the 3.8 average for large retail chains. For prospective investors evaluating the The Medicine Shoppe Or Medicine Shoppe franchise opportunity, understanding the financial parameters is paramount, even when specific brand-level disclosures are not available in the current FDD. While details regarding the specific franchise fee, total initial investment range, liquid capital requirements, net worth requirements, and ongoing fees for The Medicine Shoppe Or Medicine Shoppe are not disclosed, we can provide critical context through industry benchmarks for the "The Medicine Shoppe Or Medicine Shoppe franchise cost" and "The Medicine Shoppe Or Medicine Shoppe franchise investment." In the broader pharmacy and drug store category, typical franchise fees for comparable retail healthcare operations can range significantly, often falling between $25,000 and $50,000. The total initial investment for establishing a new community pharmacy can range from approximately $250,000 to $750,000 or more, depending heavily on factors such as real estate acquisition or leasehold improvements, initial inventory procurement, technology infrastructure (point-of-sale systems, dispensing software), licensing, regulatory compliance, and essential working capital to cover initial operational expenses. Liquid capital requirements for similar franchises often range from $100,000 to $250,000, ensuring the franchisee has sufficient immediate funds for startup and unforeseen costs, while net worth requirements can be upwards of $300,000 to $500,000 to demonstrate financial stability. Ongoing fees, typically comprising royalty fees and advertising contributions, are standard in franchising. Royalty fees for pharmacy franchises usually range from 4% to 7% of gross revenue, compensating the franchisor for ongoing support, brand usage, and system advancements. An advertising fund contribution, generally between 1% and 2% of gross revenue, supports collective marketing efforts designed to enhance brand visibility and drive customer traffic across the network. A comprehensive total cost of ownership analysis for a The Medicine Shoppe Or Medicine Shoppe franchise investment would therefore need to factor in these industry-standard benchmarks for initial outlay, ongoing operational costs, inventory management (which can represent a substantial portion of working capital, typically turning over 8-12 times per year), and the costs associated with maintaining a highly regulated healthcare environment. While specific figures for The Medicine Shoppe Or Medicine Shoppe are not currently disclosed, these industry averages provide a foundational framework for investors to structure their due diligence and financial planning when exploring this franchise opportunity. The operating model of The Medicine Shoppe Or Medicine Shoppe franchise, while specific details are not available, can be inferred from general best practices within the community pharmacy sector, designed to optimize patient care and operational efficiency. Daily operations for a typical pharmacy involve high-volume prescription dispensing, with an average U.S. pharmacy processing over 60,000 prescriptions annually. Beyond this core function, pharmacists engage in critical patient counseling, medication therapy management (MTM) services—which can significantly improve patient outcomes and generate additional revenue streams—and the administration of immunizations, a service that has seen exponential growth, with over 200 million flu shots administered annually in the U.S. alone. Retail sales of over-the-counter (OTC) medications, health and wellness products, and potentially durable medical equipment also contribute substantially to revenue. Efficient inventory management is crucial, requiring sophisticated systems to track hundreds of thousands of SKUs and ensure regulatory compliance and optimal stock levels. Staffing requirements for a community pharmacy typically include 3-5 full-time equivalents, comprising licensed pharmacists, certified pharmacy technicians (often at a 1:2 or 1:3 pharmacist-to-technician ratio depending on state regulations), and support staff for administrative and front-end retail duties. The format options for The Medicine Shoppe Or Medicine Shoppe likely emphasize an accessible, community-based retail footprint, potentially including features like drive-thru services for enhanced patient convenience or strategic partnerships with local clinics to integrate care. While specific details of the training program are not disclosed, a robust franchise system in a highly regulated industry would necessitate comprehensive initial training covering proprietary POS systems, inventory management protocols, regulatory compliance (HIPAA, state board regulations), patient care standards, and foundational business management. Ongoing corporate support would typically encompass centralized purchasing power, potentially yielding 15-20% cost savings on generic medications, national and local marketing assistance, continuous operational guidance, regular updates on evolving healthcare regulations, and integration of new technologies. Territory structure is fundamental to franchising, and it is common for systems like The Medicine Shoppe Or Medicine Shoppe to offer exclusive territories, defined by population density or geographic boundaries, to prevent intra-brand competition and ensure market penetration. For successful operators, multi-unit requirements are often a natural progression, allowing franchisees to leverage established operational efficiencies and expand their market reach, aligning with the 100% franchised model of The Medicine Shoppe Or Medicine Shoppe. Regarding financial performance, it is important to clearly state that Item 19 financial performance data is NOT disclosed in the current FDD for The Medicine Shoppe Or Medicine Shoppe. This means specific revenue, profit, or earnings claims directly attributable to The Medicine Shoppe Or Medicine Shoppe franchise units are not available for public review. Consequently, prospective investors must rely on broader industry benchmarks and their own meticulous financial projections, coupled with thorough due diligence during the discovery process. In the absence of specific disclosures, we turn to industry-wide data to provide context for the "The Medicine Shoppe Or Medicine Shoppe franchise investment." Average gross margins for community pharmacies typically range from 20% to 25% on prescription sales, with higher margins possible on OTC products and specialized services. Net profit margins for independent pharmacies can vary significantly based on operational efficiency, location, and service mix, but commonly fall within the 2% to 4% range. The average annual revenue for a well-managed independent community pharmacy can range from $3 million to $5 million, a figure heavily influenced by prescription volume, insurance contracts, and the diversification of services offered. The U.S. pharmaceutical market's overall growth trajectory, with a projected 4.5-5.0% CAGR to over $600 billion by 2028, provides a strong macroeconomic tailwind for all participants, including The Medicine Shoppe Or Medicine Shoppe franchise owners. A significant driver of profitability in modern pharmacy is the increasing shift towards specialty medications, which now account for over 50% of pharmaceutical spending and often carry higher margins due to their complexity and limited distribution. Factors influencing a pharmacy's profitability extend beyond mere prescription count to include astute inventory management, which can see inventory turnover rates of 8-12 times per year for efficiently managed operations, optimized staffing levels, effective negotiation with pharmacy benefit managers (PBMs), and the successful implementation of value-added services like compounding, immunizations, and chronic disease management programs. While specific performance numbers for The Medicine Shoppe Or Medicine Shoppe are not available, the industry's fundamental demand, consistent growth, and potential for strong operational margins provide a compelling backdrop for evaluating this franchise opportunity. Investors should prepare to engage directly with the franchisor and existing franchisees to gather anecdotal performance insights and construct their own detailed financial models. The growth trajectory of The Medicine Shoppe Or Medicine Shoppe franchise, while not detailed with historical unit count trends or net new unit figures, is defined by its current stable network of 46 wholly franchised units. This 100% franchised model signals a mature, operator-centric approach, where the corporate entity focuses entirely on supporting its franchisees rather than managing company-owned stores. The absence of company-owned units often indicates a strong belief in the entrepreneurial spirit and local market expertise of individual franchisees. Without specific data on net new units year-over-year, we can infer that the brand maintains a consistent presence and is poised for strategic expansion. Recent developments in the broader community pharmacy sector, which would undoubtedly benefit The Medicine Shoppe Or Medicine Shoppe franchise, include the expanded scope of practice for pharmacists across many states, allowing them to provide more primary care services, such as point-of-care testing and prescribing for minor ailments. Furthermore, the increasing integration of pharmacies into local healthcare ecosystems through partnerships with physician offices and hospitals creates new referral pathways and enhances service delivery. The competitive moat for The Medicine Shoppe Or Medicine Shoppe lies precisely in its commitment to personalized service and deep community integration. In a market where larger chains often prioritize speed over patient interaction, smaller, neighborhood pharmacies typically achieve significantly higher patient loyalty, with retention rates frequently exceeding 80%, compared to around 70% for more transactional retail pharmacies. This focus on building trusted relationships and offering tailored care, a hallmark of the The Medicine Shoppe Or Medicine Shoppe brand, creates a defensible position in the market. The franchise model itself provides a competitive advantage by combining the standardization and support of a national brand with the agility and local responsiveness of independent ownership. Digital transformation is another critical area, with over 70% of patients now preferring digital options for prescription refills, appointment scheduling, and health information access. The implementation of online prescription portals, mobile apps for medication reminders, and telepharmacy services are essential for modern pharmacies to remain competitive and enhance patient engagement, bolstering the long-term viability of the "The Medicine Shoppe Or Medicine Shoppe franchise opportunity." The ideal franchisee for The Medicine Shoppe Or Medicine Shoppe franchise is typically a licensed pharmacist or a healthcare professional with a profound commitment to patient care, coupled with strong business acumen and leadership capabilities. This individual should possess a deep understanding of the complexities of healthcare regulations, local market dynamics, and the nuances of community health needs. Experience in retail management or small business ownership is highly beneficial, as is a demonstrated ability to build and nurture local relationships. The role requires an operator who is not only proficient in pharmaceutical practice but also passionate about community engagement and dedicated to fostering a trusted healthcare environment. While specific multi-unit expectations are not detailed, the 100% franchised model with 46 active units suggests that The Medicine Shoppe Or Medicine Shoppe has developed a proven system that could readily support and encourage multi-unit growth for qualified and ambitious operators. This structure often attracts franchisees looking to scale their operations and leverage established efficiencies across multiple locations. Given the current unit count of 46, there remains significant potential for available territories across numerous underserved communities throughout the United States. These opportunities are particularly prevalent in areas experiencing population growth, an increasing elderly demographic, and a rising demand for accessible, local healthcare services, making the "The Medicine Shoppe Or Medicine Shoppe franchise opportunity" attractive for strategic expansion. The typical timeline from signing a franchise agreement to the grand opening of a new pharmacy can range from 6 to 12 months. This period encompasses critical stages such as site selection, lease negotiation or property acquisition, pharmacy design and build-out, securing necessary state and federal licenses, initial inventory procurement, and comprehensive staff recruitment and training. While the specific term length for the franchise agreement is not publicly available, standard franchise agreements in the industry typically range from 10 to 20 years, often with options for renewal, providing long-term stability for dedicated franchisees. The Medicine Shoppe Or Medicine Shoppe franchise represents a compelling investment thesis within the resilient and expanding healthcare sector, offering a unique blend of established brand recognition and the critical advantages of community-focused, personalized patient care. The U.S. pharmacy market, valued at $450 billion and projected to surpass $600 billion by 2028 with a 4.5-5.0% CAGR, provides a robust economic foundation for this "The Medicine Shoppe Or Medicine Shoppe franchise investment." With 46 active, wholly franchised units, the system demonstrates a proven operational model that prioritizes franchisee success and local market integration. This 100% franchised structure signals a mature, operator-centric approach, empowering entrepreneurs to thrive within a system designed for community impact and patient loyalty. While specific financial performance data (Item 19) is not disclosed in the current FDD, the industry benchmarks of 20-25% gross margins and 2-4% net profit margins for independent pharmacies, coupled with average annual revenues of $3 million to $5 million, underscore the significant potential for profitability when managed efficiently. The opportunity to deliver essential healthcare services, capitalize on an aging population, and meet the growing consumer demand for personalized care positions The Medicine Shoppe Or Medicine Shoppe franchise as a strategically sound venture for qualified individuals. This is not merely an investment in a business; it is an investment in community health, backed by a system focused on support and sustainable growth. Explore the complete The Medicine Shoppe Or Medicine Shoppe franchise profile on PeerSense to access the full suite of independent franchise intelligence data.
Other franchise sites rely on marketing materials. We use real SBA lending data to show you what's actually happening.
See actual SBA loan default rates for every franchise brand. Know which brands have borrowers who repay — and which don't.
Discover which SBA lenders fund each brand, their approval volumes, and default performance. Get matched with the right lender.
Compare any franchise against its industry benchmarks. See if it outperforms or underperforms the sector average.
The PeerSense Franchise Directory is the most comprehensive data-driven franchise research tool available. With over 6,300 franchise brands scored by real SBA data and 133,000+ mapped locations, each profile includes our proprietary Franchise Performance Index (FPI), composite health scores, SBA lending data, geographic distribution, and FDD-sourced investment details.
Unlike other franchise directories, PeerSense uses real SBA loan performance data to evaluate franchise brands. Our data comes from 100+ industry sectors and 899+ SBA lenders, giving you an objective, data-backed view of franchise performance.
The FPI is a proprietary scoring system that evaluates franchise brands on a 0-100 scale based on SBA loan repayment performance, lender diversity, geographic reach, system maturity, lending velocity, and financial transparency.
Start by browsing popular categories like Restaurants, Hotels, Fitness Centers, or Child Day Care. You can also search by name, filter by investment range, and sort by FPI score to find top performers.
Once you find a franchise, explore its full profile for SBA lending history, health scores, FDD fees, and revenue data. Then check industry benchmarks to compare it against the sector, or find specialized SBA lenders who fund that brand. Looking to buy? Browse businesses for sale with data-backed valuations.
Found the right franchise? PeerSense connects you with 500+ capital sources to fund your deal. Explore financing solutions matched to franchise acquisitions.